

CURRICULUM VITAE

Jan 10, 2025

I. PERSONAL INFORMATION

Name: Chaodong Wu
Rank: Professor
Texas A&M AgriLife Research Faculty Fellow
Presidential Impact Fellow
Campus address: Department of Nutrition
Texas A&M University
2253 TAMU, Cater-Mattil 217A
College Station, TX 77843
Phone: (979) 321 7093
Email: chaodong.wu@ag.tamu.edu

II. EDUCATION

Beijing Medical University, China. PhD in Medical Science, 09/1995-07/1998
Tongji Medical University (Wuhan), China. Master of Medical Science, 09/1992-07/1995
Hubei University of Chinese Medicine (Wuhan), China. MD, Medicine, 09/1987-07/1992

III. EXPERIENCE

A. Current Position

Date: Nov, 2020 - present: Presidential Impact Fellow
Sept 1, 2018 - present: Professor
Dec, 2015 - present: Texas A&M AgriLife Research Faculty Fellow

Current job expectation: Research, Teaching, and Service

Research

1) Sustaining a nationally recognized research program that addresses high priority needs in the area of unhealthy nutrition-related metabolic diseases such as insulin resistance, fatty liver disease, and diabetes that leads to expansion of critical knowledge, scholarly achievement, excellence in research, discovery of new and innovative technologies, an enhanced understanding of biological mechanisms or systems and/or creation of intellectual property; other duties include securing extramural funds to support ongoing research activities and effectively communicating the significance or impact of the research performed; and 2) Supervision and training of undergraduate students, M.S. and Ph.D. degree candidates and/or post-doctoral appointees in the discipline of Nutrition;

Teaching

3) Teaching undergraduate and graduate courses in Nutrition such as Nutrition and Physiological Chemistry (NUTR 475), Nutritional Biochemistry II (NUTR 642), Nutrition Seminar (NUTR 481, NUTR 681), Advanced Nutrition (NUTR 689), and Research (NUTR 485, NUTR 491, and NURT 691); other responsibilities include mentoring of students and providing academic guidance to enable success within the discipline.

Service

4) Service to the department, college, university and the general public as part of the ongoing mission of a Land Grant Institution.

B. Past Positions and Experiences

12/2015 - 08/2018: Texas A&M University, College Station, TX. Associate Professor
Texas A&M AgriLife Research Faculty Fellow

09/2013 - 08/2018: Texas A&M University, College Station, TX. Associate Professor

04/2007 - 08/2013: Texas A&M University, College Station, TX. Assistant Professor

02/2006 - 03/2007: Hoffmann-La Roche, Nutley, New Jersey. Principal Scientist

08/2003 - 02/2007: The University of Minnesota, Minneapolis, MN. Research Associate

08/1998 - 07/2003: The University of Minnesota, Minneapolis, MN. Postdoctoral Associate

09/1995 - 07/1998: Beijing Medical University, Beijing, China. Research Assistant

09/1992 - 07/1995: Tongji Medical University, Wuhan, China. Research Assistant

09/1991 - 07/1992: Hubei Hospital, Hubei University of Chinese Medicine, Wuhan, Intern

IV. RESEARCH

A. Research Support

External competitive

1-10-JF-54 Junior Faculty Award, Wu (PI) 01/01/10-12/31/12

American Diabetes Association \$386,400

Regulation of adipose tissue inflammatory response in diet-induced diabetes: the role of PFKFB3

The goal of this study is to gain insight of the novel and unique role played by PFKFB3 in regulating the adipose tissue inflammatory response in diet-induced diabetes.

Role: PI (25%)

12BGIA9050003 Beginning Grant-in-Aid, Wu (PI) 01/01/12-12/31/13

American Heart Association \$140,000

PFKFB3 regulation of macrophage polarization and atherosclerosis

The goal of this project is to investigate the regulatory mechanisms of PFKFB3 for macrophage polarization in relation to the development of atherosclerosis.

Role: PI (15%)

Curriculum Vitae: Chaodong Wu, MD, PhD

1R01 DK095862, Wu (PI) 04/15/13-03/31/19
NIDDK/NIH \$1,604,850

Protective role of adenosine 2A receptor in NAFLD
The goal of this study is to define a novel protective role for adenosine 2A receptor (A_{2A}R) in non-alcoholic fatty liver disease (NAFLD).
Role: PI (25%)

1R01 DK095828, Wu (PI) 05/05/13-04/30/18
NIDDK/NIH \$1,257,578

Metabolic regulation of adipocyte-macrophage crosstalk in obesity
The goal of this study is to define the novel role of PFKFB3 in regulating adipocyte-macrophage crosstalk in relation to insulin resistance in obesity.
Role: PI (30%)

1-13-BS-214-BR Research Award (Bridge funding), Wu (PI) 11/01/13-10/31/14
American Diabetes Association \$60,000

Hepatocyte adenosine 2A receptor regulates liver lipogenesis and inflammatory responses in DIO
The goal of the bridge funding is to generate new preliminary data for resubmission to ADA or other funding agency.
Role: PI (1%)

1-17-IBS-145 Innovative Basic Science Award Wu (PI) 01/01/17-12/31/19
American Diabetes Association \$345,000

Novel role for adenosine kinase in the control of hepatic gluconeogenesis
The goal of this study is to define a novel role for adenosine kinase in regulating hepatocyte gluconeogenesis and systemic glucose homeostasis.
Role: PI (5%)

5R01 DK095862-05, Wu (PI) 04/01/17-03/31/18
NIDDK/NIH \$31,724

Protective role of adenosine 2A receptor in NAFLD
YR 5 Revised
The goal of this study is to define a novel protective role for adenosine 2A receptor (A_{2A}R) in non-alcoholic fatty liver disease (NAFLD).
Role: PI (25%)

1R01 DK124854, Wu (PI) 04/01/20-03/31/24
NIDDK/NIH \$1,827,291

ADK Regulation of Fat Metabolism and Insulin Sensitivity
The goal of this study is to elucidate a new paradigm of fat metabolism and insulin sensitivity, in which ADK dysregulates hepatocyte-macrophage crosstalk to increase hepatic steatosis and insulin resistance.
Role: PI (25%)

1R01 DK135881, Glaser/Wu (MPI) 04/01/23-03/31/27

Curriculum Vitae: Chaodong Wu, MD, PhD

- NIDDK/NIH** \$1,922,684
Role of STING in Cholestatic Liver Injury
The goal of this study is to elucidate a role for stimulator of the interferon genes (STING) in regulating macrophage activation and cholangiocyte senescence-associated secretory phenotype as it relates to the pathogenesis of biliary liver injury and liver fibrosis.
Dr. Wu oversees the studies addressing how the STING in macrophages responds to cholangiocyte factors and regulates cholangiocyte functions.
Role: MPI (15%)
- RP160822, Zhang X (PI)** 06/01/16 - 31/05/18
Cancer Prevention and Research Institute of Texas (CPRIT) \$199,958
Exploring a plant viral suppressor as an anti-cancer drug
The goal of this study is to engineer a plant virus-encoded TrAP protein that specifically inhibits eukaryotic histone methyltransferases to control cell proliferation and tumorigenesis in human cells.
Role: Co-PI (0%)
- 2017-06957 NIFA Grant, Wu (Co-PI)/Awika (PI)** 03/01/18-02/28/21
NIFA/USDA \$461,528*
Mechanisms for synergistic interactions of combined cereal flavones and legume 3-hydroxyflavones against inflammation
The goal of this study is to elucidate how bioactive components of crop products generate beneficial effects on inflammation.
Role: Co-PI (10%)
* A total of \$200,475 (including direct costs at a total of \$135,000) has been budgeted for Dr. Wu.
- 5R01 DK126833, Wu (Co-PI)/Hoyt (PI)** 12/21/20-11/30/25
NIDDK/NIH \$739,780.38*
Multiparametric ultrasound imaging for early detection of nonalcoholic fatty liver disease
The goal of this study is to introduce and validate a safe, cost-effective mpUS imaging technology that can noninvasively detect, accurately stage, and reliably monitor NAFLD.
Role: Co-PI (12.5%)
* A total of \$84,854 has been budgeted for Dr. Wu.
- 1-10-BS-76 Research Award, Huo (PI)** 01/01/10-12/31/13
American Diabetes Association \$322,000*
Macrophage A_{2A} receptor regulates glucose homeostasis
The goal of this study is to define the mechanisms underlying the role of macrophage A_{2A}R in the regulation of glucose homeostasis
Role: Co-Investigator (5%)
- 11BGIA7850037, Zhou (PI)** 07/01/11-06/30/13
American Heart Association \$140,000*

Curriculum Vitae: Chaodong Wu, MD, PhD

Regulation of CVD risk in obesity: the role of macrophage miR-223 in adipose tissue inflammation

The goal of this project is to investigate the regulatory mechanisms of miR-223 in macrophage function contributing to obesity related cardiovascular diseases.

Role: Co-Investigator (5%)

DK132891-01, Alpini (PI)

04/01/22-01/31/26

NIDDK/NIH

\$2,268,572*

Role of Sensory Innervation in High Fat Diet-Induced Hepatotoxicity

The goal of this project is to provide insight for novel therapeutic approaches for NAFLD/NASH and other liver diseases characterized by ductular reaction and hepatobiliary fibrosis.

Role: Co-Investigator (8.3%)

* A total of \$140,686 is dedicated to Dr. Wu's research.

Internal competitive

As PI

Grand Challenge Grant Wu (PI)/Chew (MPI)

12/05/14-08/31/17

College of Agriculture and Life Sciences of Texas A&M University

\$150,000

Big Idea: Formation of Texas A&M Nutrition Obesity Research Center

The goal of this grant is to obtain seed funding to drive an integrated program on nutrition obesity research.

Role: PI

Institutional Support for Nutrition Obesity Research Wu (PI)

07/01/15-06/30/16

Texas A&M AgriLife Research

\$150,000

Acquiring the Promethion Metabolic Measurement System

The goal of this funding is to purchase the next generation of mouse metabolic phenotyping system for enhancing the ongoing nutrition obesity research at Texas A&M University.

Role: PI

IHA RFP

01/01/25-03/01/26

Texas A&M AgriLife Research

\$225,000

Unraveling the potential of nutritional intervention for liver fibrosis in people living with HIV

The goal of this funding is to validate the potential of nutrition intervention for managing liver fibrosis associated with HIV infection on anti-retroviral therapy.

Role: PI

As Mentor

Undergraduate student research funding

Spring 2011

\$600

Mr. Kha Lai is supported by departmental funds to conduct undergraduate research in the laboratory of Dr. Chaodong Wu

Undergraduate mentorship grant Summer 2011 \$500 + \$500
Mr. Shih-Lung Woo is supported by funds from the College of Agriculture and Life Science and by the Department of Nutrition and Food Science.

Undergraduate student research funding Spring 2013 \$1,000
Ms. Ting Qi is supported by departmental funds to conduct undergraduate research in the laboratory of Dr. Chaodong Wu

Undergraduate student research funding Fall 2015 \$1,000
Ms. Ngoc Tran is supported by departmental funds to conduct undergraduate research in the laboratory of Dr. Chaodong Wu

Internal selected

T3 Grant, Project ID: 1064, Wu (PI) 01/01/19-12/31/20 \$33,000
Texas A&M University T3 Grant, Round Two
Interplay between gut microbiome and innate immunity in non-alcoholic steatohepatitis
The goal of this project is to elucidate whether and how gut microbiome interplays with STING signaling in macrophages as it relates to the pathogenesis of NASH.
Role: PI

T3 Grant, Project ID: 1929, Wu (PI) 01/01/21-12/31/22 \$30,000
Texas A&M University T3 Grant, Round Four
Role of STING in immunopathology of hepatocellular carcinoma
The goal of this project is to elucidate a role for the STING in myeloid cells in regulating the development and progression of primary liver cancer.
Role: PI

Presidential Impact Fellow, Wu 01/01/21-12/31/23 \$75,000
Texas A&M University
The goal of this award is to make Presidential Impact Fellows' research, scholarship, and other professional contributions more highly recognized nationally and internationally and to increase the likelihood that Presidential Impact Fellows will receive increasingly prestigious professional recognitions.

B. Publications

Refereed/Peer-Reviewed Research Articles

1. Luo M, Li MZ, Ye WY, Lin BY, and **Wu CD**. Changes in the levels of plasma tumor necrosis factor in rabbits with endotoxin-induced DIC. *Chin Criti Care Med*, 1995;7:65-67.

2. **Wu CD**, Li MZ, Zhang YP, Lin BY., Luo M., and Xu LJ. Effects of reducing injection on plasma TNF- α and IL-6 levels in rabbits with endotoxin-induced DIC. *Chin J Integra Tradi Wester Med*, 1995, 15:356-358.
3. **Wu C.**, Li M., Chen C, Zhang M. Endotoxin-induced liver injury and plasma tumor TNF α , IL6 level changes in rabbits. *Chin J Dig Dis*, 1995, 15:256-258. Chinese version.
4. **Wu C.**, Li M., Chen C., and Zhang M. Endotoxin-induced liver injury and changes in the levels of plasma tumor necrosis factor- α and interleukin-6 in rabbits. *Chin Med J*, 1995,108:548-550. English version
5. **Wu CD**, Li MZ, Zhang MF, Wang KF., Xu LJ., Li HG. Effects of Traditional Chinese medicine reducing on interleukin-6 and acute phase proteins in rabbits with endotoxin-induced disseminated intravascular coagulation. *Chin Criti Care Med*, 1996;8:3-4.
6. **Wu CD.**, and Tao QM. Cloning and sequencing of E2/NS1 gene from a Chinese genotype III isolate of hepatitis C virus. *Natl Med J China*, 1998,78:115-117.
7. **Wu CD.**, and Tao QM. Comparison between homologies of E2/NS1 gene from genotype III Chinese isolates of hepatitis C virus and that from reported isolates. *Chin Med J*, 1998,111:807-809.
8. **Wu CD.**, Gao JE., and Tao QM. Stable expression E2 glycoprotein of hepatitis C virus in mammalian cell. *Chin Biochem Mol Bio J*, 1998,14:15-19.
9. **Wu CD.**, and Tao QM. E2 glycoprotein of genotype III Chinese isolates of hepatitis C virus expressed in mammalian cell as antigen for anti-E2 detection. *Chin Med Sci J*, 1998,13:77-79.
10. **Wu CD.**, Tao QM. Du SC and Chang JH. Amplification of E2/NS1 gene derived from a genotype III Chinese isolate of hepatitis C virus and construction of mammalian expression plasmid. *J Beijing Med Univ*, 1998,30:371.
11. **Wu CD.**, Tao QM. and Feng B.F. Inducing antibody response against E2 glycoprotein of hepatitis C virus in BALB/C mice by plasmid DNA based immunization. *J Beijing Med Univ*, 1998,30:395-396.
12. **Wu CD.**, and Tao QM. Homologies of E2/NS1 gene derived from a genotype III Chinese isolate of hepatitis C virus to that from reported isolates. *Chin Biochem Mol Bio J*, 1998,14:553-556.
13. **Wu CD.**, Tao QM., and Feng BF. Antibody response to E2 glycoprotein induced in mice by immunization of plasmid DNA containing sequence derived from a Chinese genotype III/2a isolate of hepatitis C virus. *Chin Med J*, 1999, 112:166-168.
14. Zhu C, **Wu C.**, and Tao Q. Detection of antibody against E2 glycoprotein in sera from hepatitis C patients. *Acta Universitatis Scieniae Medicinae Chongqince*. 1999,24:262-263.
15. Zhu C, **Wu C.**, Tao Q, and Feng B. Enzyme immune assay for detecting antibody against hepatitis C virus E2 glycoprotein. *Chin J Med Lab Sci*, 1999,22:21-221.
16. Zhu C, **Wu C.**, Tao Q, Feng B. and Chang J. Expression of glycoprotein of hepatitis C virus in mammalian cell and application of purified protein for detection of antibody against E2 in hepatitis C patients. *Chin J Hepatol*, 1999, 7(4):214-6.
17. **Wu C.**, Okar D.A., Newgard C.B., and Lange A.J. Suppression of hepatic glucose production lowers blood glucose by overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in mouse liver. *J Clin Invest*, 2001,107:91-98.

18. **Wu C.**, Okar D.A., Newgard C.B., and Lange A.J. Increasing fructose-2,6-bisphosphate overcomes hepatic insulin resistance of type 2 diabetes. *Am J Physiol*, 2002, 282:E38-E45.
19. Choi I-Y. , **Wu C.**, Okar D.A., Lange A.J and Grutter R. Elucidation of the role of fructose-2,6-bisphosphate in regulation of glucose fluxes in mice using *in vivo* ¹³C NMR measurements of hepatic carbohydrate metabolism. *Eur J Biochem*, 2002,269:4418-4426.
20. **Wu C.**, Okar D.A., Stoeckman A.K., Peng L.J., A.H. Herrera, J.E. Herrera, Towle H.C., and Lange A.J. A potential role for fructose-2,6-bisphosphate in insulin stimulation of hepatic glucokinase gene expression. *Endocrinology*, 2004,145:650-658.
21. Donthi R.V., Ye G., **Wu C.**, McClain D.A., Lange A.J., and Epstein P.N. Cardiac expression of kinase deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function and reduces insulin sensitivity. *J Biol Chem*. 2004, 279: 48085-48090.
22. Baar R.A., Dingfelder C.S., Smith L.A., Bernlohr D.A., **Wu C.**, Lange A.J., and Parks E.J. Investigation of *in vivo* fatty acid metabolism in AFABP/aP2^{-/-} mice. *Am J Physiol*, 2005, 288:E187-193.
23. Payne V.A., Arden C., **Wu C.**, Lange A.J. and Agius L. Dual role of phosphofructokinase-2/fructose bisphosphatase-2 in regulating the compartmentation and expression of glucokinase in hepatocytes. *Diabetes*, 2005,54:1949-1957.
24. **Wu C.**, Kang J., Peng L-J., Li H., Khan S.A., Hillard C.J., Okar D.A., and Lange A.J. Enhancing hepatic glycolysis reduces obesity: Differential effects on lipogenesis depend on site of glycolytic modulation. *Cell Metabolism*, 2005, 2: 131-140.
25. Niswender, C.M., Willis, B.S., Wallen A., Sweet I.R., Jetton T.L., Thompson B.R., **Wu C.**, Lange A.J., and McKnight G.S. Cre recombinase-dependent expression of a constitutively active mutant allele of the catalytic subunit of protein kinase A. *Genesis*, 2005, 43: 108-118.
26. **Wu C.**, Khan SA, Peng Li-Jen, Li H., Camela S., and Lange A.J. Perturbation of glucose flux in the liver by decreasing fructose-2,6-bisphosphate levels causes hepatic insulin resistance and hyperglycemia. *Am J Physiol Endocrinol Metab*, 2006, 291: E536-543.
27. Smith W.E., Langer S., **Wu C.**, Baltrusch S., and Okar D.A. Molecular coordination of hepatic glucose metabolism by the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase:Glucokinase complex. *Mol Endocrinol*. 2007, 21: 1478-1487.

Since appointment as Assistant Professor at TAMU (in April 2007)

28. Wang H., Zhang W., Zhu C., Bucher C., Blazar BR., Zhang C., Chen JF., Linden J., **Wu C (co-corresponding author)**, and Huo Y. Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis. *Arterioscler Thromb Vasc Biol* 2009, 29:1046-1052.
29. Huo Y, Guo X (**PhD student**), Li H, Wang H, Zhang W, Wang Y, Zhou H, Gao Z, Telang S, Chesney J, Chen YE, Ye J, Chapkin RS, and **Wu C (corresponding author)**. Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity

- but exacerbates systemic insulin resistance and adipose tissue inflammatory response. *J Biol Chem*, 2010, 285: 3713-3721. PMID: PMC2823512
30. Wang H, Zhang W, Tang R, Zhu C, Bucher C, Blazar B, Geng J, Zhang C, Linden J, **Wu C** (*co-corresponding author*), and Huo Y. (2010). Adenosine receptor A_{2A} deficiency in leukocytes increases arterial neointima formation in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol*, 2010, 30:915-922.
 31. Zhang W., Wang J., Wang H., Tang R., Belcher JD., Viollet B., Geng JG, Zhang C., **Wu C**, Slungaard A., Zhu C, and Huo Y. Adenosine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway. *Arterioscler Thromb Vasc Biol*, 2010, 30:1000-1006
 32. Guo X (**PhD student**), Xu K, Zhang J, Li H, Zhang W, Wang H, Lange AJ, Chen Y, Huo Y, and **Wu C** (*corresponding author*). Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of PPAR γ activation in mice. *J Biol Chem*, 2010, 285:23711-23720. PMID: PMC2911274
 33. Zhuang G., Meng C., Guo X. (**PhD student**), Cheruku PS., Shi L., Xu H. (**PhD student**), Li H., Wang G., Evans A., Safe S., **Wu C**. (*co-corresponding author*), and Zhou B. (2012) A novel regulator of macrophage activation: miR-223 in obesity associated adipose tissue inflammation. *Circulation*, 2012, 125: 2892-2903.
 34. Huo Y, Guo X (**PhD student**), Li H, Xu H (**PhD student**), Halim V (**MS student**), Zhang W, Wang H, Fan YY, Ong KT, Woo SL (**MS student**), Chapkin RS, Mashek DG, Chen Y, Dong H, Lu F, Wei L, **Wu C**. (*corresponding author*). Targeted overexpression of inducible 6-phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against diet-induced insulin resistance and inflammatory responses. *J Biol Chem*, 2012, 287:21492–21500. PMID: PMC3375570
 35. Guo X. (**PhD student**), Li H., Xu H. (**PhD student**), Halim V. (**MS student**), Zhang W., Wang H., Ong K.T., Woo S.L. (**MS student**), Walzem R.L., Mashek D.G., Dong H., Lu F., Wei L., Huo Y, and **Wu C** (*corresponding author*). Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. *PLoS One*, 2012, 7(6): e392862012. PMID: PMC3387145
 36. Monk JM, Hou TY, Turk HF, Weeks B, **Wu C**, McMurray DN, and Chapkin RS. Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis. *PLoS One*, 2012, 7(11): e49739. PMID: PMC3500317
 37. Guo X. (**PhD student**), Li H., Xu H. (**PhD student**), Halim V. (**MS student**), Thomas LN, Woo SL (**MS student**), Huo Y, Chen YE, Sturino JM, and **Wu C** (*corresponding author*). Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPAR γ activation on diet-induced intestine inflammatory response. *J Nutr Biochem*, 2013, 24:770-5. PMID: PMC3584194
 38. Wei S, Wang H, Zhang G, Lu Y, An X, Ren S, Wang Y, Chen Y, White J, Zhang C, Simon D, **Wu C**, Li Z, and Huo Y. Platelet IKK β deficiency increases mouse arterial neointima formation via delayed glycoprotein Iba shedding. *Arterioscler Thromb Vasc Biol* 2013, 33:241-8. PMID: PMC3755353
 39. Li H., Guo X. (**PhD student**), Xu H. (**PhD student**), Woo S.L. (**MS student**), Halim V. (**MS student**), Morgan C., and **Wu C** (*corresponding author*). A role for inducible 6-phosphofructo-2-kinase in the control of neuronal glycolysis. *J Nutr Biochem*, 2013 Jun;24(6):1153-8. doi: 10.1016/j.jnutbio.2012.08.016.

40. Chen Y, Mu P, He S, Tang X, Guo X (**PhD student**), Li H, Xu H (**PhD student**), Woo S-L (**MS student**), Qian X, Zeng L, and **Wu C** (*corresponding author*). Gly482Ser mutation blunts the effects of PGC-1 α on decreasing fat deposition and on stimulating PEPCK expression in hepatocytes. *Nutr Res*, 2013 Apr;33(4):332-9. doi: 10.1016/j.nutres.2013.02.003

Since promotion to Associate Professor (in Sept 2013)

41. Woo SL (**PhD student**), Xu H (**PhD student**), Li H, Zhao Y (**Postdoc**), Hu X (**Postdoc**), Zhao J (**Visiting PhD student**), Guo X (**Postdoc**), Guo T (**MS student**), Botchlett R (**PhD student**), Qi T (**MS student**), Pei Y (**PhD student**), Zheng J (**Postdoc**), Xu Y, An X, Chen L, Chen L, Li Q, Xiao X, Huo Y, and **Wu C** (*corresponding author*) (2014) Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. *PLoS One*, 2014, 9:e91111. PMID: PMC3956460
42. Xu Y, An X, Guo X (**Postdoc**), Habtetsion TG, Wang Y, Xu X, Li Q, Li H, Zhang C, Caldwell RB, Fulton DJ, Su Y, Hoda MN, Zhou G, **Wu C** (*co-corresponding author*), and Huo Y. (2014) Endothelial PFKFB3 plays a critical role in angiogenesis. *Arterioscler Thromb Vasc Biol*, 2014, 34:1231-1239 PMID: PMC4120754
43. Xu H (**PhD student**), Li H, Woo SL (**PhD student**), Kim SM, Shende VR, Neuendorff N, Guo X (**Postdoc**), Guo T (**MS student**), Qi T (**MS student**), Pei Y (**PhD student**), Zhao Y (**Postdoc**), Hu X (**Postdoc**), Zhao J (**visiting PhD student**), Chen L, Chen L, Ji JY, Alaniz RC, Earnest DJ, **Wu C** (*corresponding author*). (2014) Myeloid cell-specific disruption of Period1 and Period2 exacerbates diet-induced inflammation and insulin resistance. *J Biol Chem*, 2014, 289:16374-16388. PMID: PMC4047405
44. Shannonhouse JL, Urbanski HF, Woo SL (**PhD student**), Fong LA, Goddard SD, Lucas WF, Jones ER, **Wu C**, Morgan C. Aquaporin-11 control of testicular fertility markers in Syrian hamsters. *Mol Cell Endocrinol*. 2014 Jun 25;391(1-2):1-9. doi: 10.1016/j.mce.2014.04.011.
45. Ming Y, Hu X, Song Y, Liu Z, Li J, Gao R, Zhang Y, Mei H, Guo T, Xiao L, Wang B, **Wu C**, Xiao X. (2014) CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo. *PLoS One*. 2014, 9(7):e102102 PMID: PMC4087031
46. Shi L, Ko ML, Huang CC, Park SY, Hong MP, **Wu C**, Ko GY. (2014) Chicken embryos as a potential new model for early onset type I diabetes. *J Diabetes Res*, 2014;2014:354094. doi: 10.1155/2014/354094. Epub 2014 Jul 13.
47. Song Z, Liu Y, Hao B, Yu S, Zhang H, Liu D, Zhou B, Wu L, Wang M, Xiong Z, **Wu C**, Zhu J, Qian X. (2014) Ginsenoside Rb1 prevents H₂O₂-induced HUVEC senescence by stimulating sirtuin-1 pathway. *PLoS One*, 2014;9(11):e112699. doi: 10.1371/journal.pone.0112699. eCollection 2014. PMID: PMC4227851
48. Zeng T, Zhou J, He L, Zheng J, Chen L, **Wu C**, Xia W. (2016) Blocking nuclear factor-kappa B protects against diet-induced hepatic steatosis and insulin resistance in mice. *PLoS One*, 2016; 11(3):e0149677. doi: 10.1371/journal.pone.0149677. eCollection 2016. PMID: PMC4773172

49. Guo T (**MS student**), Woo SL (**PhD student**), Guo X (**Postdoc**), Li H, Zheng J (**Postdoc**), Botchlett R (**PhD student**), Liu M (**Postdoc**), Xu H (**PhD student**), Cai Y (**visiting PhD student**), Li X, Li Q, Xiao X, Huo Y, and **Wu C** (*corresponding author*). (2016) Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. *Sci Rep*, 2016;6:22612. doi: 10.1038/srep22612. PMCID: PMC4776174
50. Liu L, Li Q, Xiao X, **Wu C**, Gao R, Peng C, Li D, Zhang W, Du T, Wang Y, Yang S, Zhen Q, Ge Q. (2016) miR-1934, downregulated in obesity, protects against low-grade inflammation in adipocytes. *Mol Cell Endocrinol*, 2016 Jun 15;428:109-17. doi: 10.1016/j.mce.2016.03.026.
51. Chen L, Zhao J (**visiting PhD student**), Tang Q, Li H, Zhang C, Yu R, Zhao Y (**Postdoc**), Huo Y, and **Wu C** (*corresponding author*). (2016) PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs. *Sci Rep*, 2016 Apr 15;6:24324. doi: 10.1038/srep24324. PMID: 27079271.
52. Hu X, Zhang Q, Zheng J, Kong W, Zhang H, Zeng T, Zhang JY, Min J, Wu C, and Chen L. (2017) Alteration of FXR phosphorylation and sumoylation in liver in the development of adult catch-up growth. *Exp Biol Med* (Maywood) 2017 Feb;242(3):297-304. doi: 10.1177/1535370216641788.
53. Botchlett R (**PhD student**), Li H, Guo X (**Postdoc**), Qi T (**MS student**), Zhao J, Zheng J, Woo SL (**PhD student**), Pei Y (**PhD student**), Liu M (**Postdoc**), Hu X, Chen G, Guo T (**MS student**), Yang S, Li Q, Xiao X, Huo Y, and **Wu C** (*corresponding author*). (2016) Glucose and palmitate differentially regulate PFKFB3/iPFK2 and inflammatory responses in mouse intestinal epithelial cells. *Sci Rep*, 2016,6:28963. doi: 10.1038/srep28963.
54. Yang S, Li T, Gao R, Liu L, Peng C, Cheng Q, Mei M, Song Y, Xiang X, **Wu C**, Xiao X, and Li Q. (2017) Dysregulated autophagy in hepatocytes promotes bisphenol A induced hepatic lipid accumulation in male mice. *Endocrinology*, 2017 Sep 1;158(9):2799-2812. doi: 10.1210/en.2016-1479.
55. Lv Q, Gao R, Peng C, Yi J, Liu L, Yang S, Li D, Hu J, Luo T, Mei M, Song Y, **Wu C**, Xiao X, and Li Q. (2017) Bisphenol A promotes hepatic lipid deposition involving Kupffer cells M1 polarization in male mice *J Endocrinol*, 2017 Aug;234(2):143-154. doi: 10.1530/JOE-17-0028.
56. Shi X, Li X, Hou Y, Cao X, Zhang Y, Wang H, Wang H, Peng C, Li J, Li Q, **Wu C**, and Xiao X. (2017) Paternal hyperglycemia in rats exacerbates the development of obesity in offspring. *J Endocrinol*, 2017 Aug;234(2):175-186. doi: 10.1530/JOE-17-0082.
57. Qi T (**MS student**), Chen Y, Li H, Pei Y (**PhD student**), Woo SL (**PhD student**), Guo X (**Postdoc**), Jiajia Zhao (**visiting PhD student**), Qian X, Awika J, Huo Y, and **Wu C** (*corresponding author*). (2017) A role for PFKFB3/iPFK2 in metformin suppression of adipocyte inflammatory responses. *J Mol Endocrinol*, 2017 Jul;59(1):49-59. doi: 10.1530/JME-17-0066.
58. Zheng J, Xiao KL, Chen L, **Wu C**, Hu X, Zeng T, Chen XQ, Li WJ, Deng X, Li H, Li YM. (2017) Insulin sensitizers improve the GLP-1 secretion and the amount of intestinal L cells on high-fat-diet-induced catch-up growth. *Nutrition*. 2017,39-40:82-91. doi: 10.1016/j.nut.2017.01.002. Epub 2017 Jan 12.

59. Wang H, Shao Y, Yuan F, Feng H, Li N, Zhang H, **Wu C**, and Liu Z. (2017) Fish oil feeding modulates the expression of hepatic microRNAs in a Western-style diet-induced non-alcoholic fatty liver disease rat model. *Biomed Res Int*, 2017;2017:2503847. doi: 10.1155/2017/2503847. Epub 2017 Jun 12.
60. Guo X, (**Postdoc**), Shu C, Li H, Pei Y (**PhD student**), Woo SL (**PhD student**), Zheng J (**Postdoc**), Liu M (**Postdoc**), Xu H (**PhD student**), Botchlett R (**PhD student**), Guo T (**MS student**), Cai Y (**visiting PhD student**), Gao X, Zhou J (**PhD student**), Chen L (**MS student**), Li Q, Xiao X, Xie L, Zhang KK, Ji JY, Huo Y, Meng F, Alpini G, Li P, and **Wu C (corresponding author)**. (2017) Cyclic GMP-AMP ameliorates diet-induced metabolic dysregulation and regulates proinflammatory responses distinctly from STING activation. *Sci Rep*, 2017 Jul 25;7(1):6355. doi: 10.1038/s41598-017-05884-y.
61. Xu Y, Wang Y, Yan S, Yang Q, Zhou Y, Zeng X, Liu Z, An X, Toque HA, Dong Z, Jiang X, Fulton DJ, Weintraub NL, Li Q, Bagi Z, Hong M, Boison D, **Wu C** and Huo Y. Intracellular adenosine alters epigenetic programming in endothelial cells to promote angiogenesis. *EMBO Mol Med*. 2017 Sep;9(9):1263-1278.
62. Liu Z, Yan S, Wang J, Xu Y, Wang Y, Zhang S, Xu X, Yang Q, Zeng X, Zhou Y, Gu X, Lu S, Fu Z, Fulton DJ, Weintraub NL, Caldwell RB, Zhang W, **Wu C**, Liu XL, Chen JF, Ahmad A, Kaddour-Djebbar I, Al-Shabrawey M, Li Q, Jiang X, Sun Y, Sodhi AK, Smith LEH, Hong M, and Huo Y, (2017) Endothelial adenosine receptor 2A mediated glycolysis is essential for pathological retinal angiogenesis. *Nat Commun*, 2017 Sep 19;8(1):584.
63. Xu Y, Wang Y, Yan S, Yang Q, Zhou Y, Zeng X, Liu Z, An X, Toque HA, Dong Z, Jiang X, Fulton DJ, Weintraub NL, Li Q, Bagi Z, Hong M, Boison D, **Wu C**, Huo Y. Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. *Nat Commun*, 2017 Oct 16;8(1):943.
64. Ma L, Hu J, Li J, Yang Y, Zhang L, Zou L, Gao R, Peng C, Wang Y, Luo T, Xiang X, Qing H, Xiao X, **Wu C**, Wang Z, He JC, Li Q, Yang S. (2017) Bisphenol A promotes hyperuricemia via activating xanthine oxidase. *FASEB J*. 2017 Oct 17. pii:fj.201700755R. doi: 10.1096/fj.201700755R. [Epub ahead of print].
65. Wan Y, McDaniel K, Wu N, Ramos-Lorenzo S, Glaser T, Venter J, Francis H, Kennedy L, Sato K, Zhou T, Kyritsi K, Huang Q, Annable T, **Wu C**, Glaser S, Alpini G, Meng F. (2017) Regulation of Cellular Senescence by miR-34a in Alcoholic Liver Injury. *Am J Pathol*. 2017 Dec;187(12):2788-2798. doi: 10.1016/j.ajpath.2017.08.027.
66. Cai Y (**visiting PhD student**), Li H, Liu M (**Postdoc**), Pei Y (**PhD student**), Zheng J (**Postdoc**), Zhou J (**PhD student**), Luo X (**visiting PhD student**), Huang W (**visiting PhD student**), Ma L (**visiting PhD student**), Yang Q, Guo S, Xiao X, Li Q, Zeng T, Meng F, Francis H, Glaser S, Chen L, Huo Y, Alpini G, **Wu C (corresponding author)**. (2018) Disruption of Adenosine 2A Receptor Exacerbates NAFLD through Increasing Inflammatory Responses and SREBP1c Activity. *Hepatology*. 2018 Jul;68(1):48-61. doi: 10.1002/hep.29777. Epub 2018 May 10.
67. Ehrlich L, O'Brien A, Hall C, White T, Chen L, Wu N, Venter J, Scrushy M, Mubarak M, Meng F, Dostal D, **Wu C**, Lairmore TC, Alpini G, Glaser S. (2018) α 7-nAChR Knockout Mice Decreases Biliary Hyperplasia and Liver Fibrosis in

- Cholestatic Bile-Duct Ligated Mice. *Gene Expr.* 2018 Mar 26. doi:10.3727/105221618X15216453076707. [Epub ahead of print]
68. Wu N, McDaniel K, Zhou T, Lorenzo S, **Wu C**, Huang L, Chen D, Annable T, Francis H, Glaser S, Alpini G, and Meng F. (2018) Knockout of microRNA-21 attenuates alcoholic hepatitis through VHL/NF- κ B signaling pathway in hepatic stellate cells. *Am J Physiol Gastrointest Liver Physiol*, 2018 May 31. doi:10.1152/ajpgi.00111.2018. [Epub ahead of print]
69. Zhou T, Wu N, Meng F, Venter J, Giang TK, Francis H, Kyritsi K, **Wu C**, Franchitto A, Alvaro D, Marzioni M, Onori P, Mancinelli R, Gaudio E, Glaser S, Alpini G. (2018) Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2^{-/-} mice by diminishing senescence of cholangiocytes. *Lab Invest.* 2018 Jul 5. doi: 10.1038/s41374-018-0093-9. [Epub ahead of print]
70. Wu N, Meng F, Zhou T, Venter J, Giang TK, Kyritsi K, Wu C, Alvaro D, Onori P, Mancinelli R, Gaudio E, Francis H, Alpini G, Glaser S, Franchitto A. (2018) The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor (TGF)- β 1-mediated biliary senescence. *Am J Pathol.* 2018 Oct;188(10):2264-2280. doi: 10.1016/j.ajpath.2018.06.015. Epub 2018 Jul 21.

Since last promotion to Professor (in Sept 2018)

71. Luo X (**visiting PhD student**), Li H, Ma L (**visiting PhD student**), Zhou J (**PhD student**), Guo X, Woo SL, Pei Y (**PhD student**), Knight LR, Deveau M, Chen Y, Qian X, Xiao X, Li Q, Chen X, Huo Y, McDaniel K, Francis H, Glaser S, Meng F, Alpini G, **Wu C** (**corresponding author**). (2018) Expression of STING Is Increased in Liver Tissues from Patients With NAFLD and Promotes Macrophage-mediated Hepatic Inflammation and Fibrosis in Mice. *Gastroenterology.* 2018 Dec;155(6):1971-1984.e4. doi: 10.1053/j.gastro.2018.09.010. Epub 2018 Sep 10.
72. Xu H, Fu Q, Zhou Y, Xue C, Olson P, Lynch EC, Zhang KK, **Wu C**, Murano P, Zhang L, Xie L. (2018) A long-term maternal diet intervention is necessary to avoid the obesogenic effect of maternal high-fat diet in the offspring. *J Nutr Biochem* 2018 Dec;62:210-220. doi: 10.1016/j.jnutbio.2018.09.008. Epub 2018 Sep 22.
73. Hou Y, Cao X, Hu X, Li X, Shi X, Wang H, Peng C, Li J, Li J, Li Q, **Wu C**, Xiao X. (2018) CMHX008, a PPAR γ partial agonist, enhances insulin sensitivity with minor influences on bone loss. *Genes Dis.* 2018 Jun 6;5(3):290-299. doi: 10.1016/j.gendis.2018.05.004. eCollection 2018 Sep.
74. Pei Y (PhD student), Li H, Cai Y (visiting PhD student), Zhou J (PhD student), Luo X (Visiting PhD student), Ma L (Visiting PhD student), McDaniel K, Zeng T, Chen Y, Qian X, Huo Y, Glaser S, Meng F, Alpini G, **Wu C** (**corresponding author**). (2018) Regulation of Adipose Tissue Inflammation by Adenosine 2A Receptor in Obese Mice. 2018 *J Endocrinol*, 2018 Dec 1;239(3):365-376. doi: 10.1530/JOE-18-0169.
75. Li X, Shi X, Hou Y, Cao X, Gong L, Wang H, Li J, Li J, **Wu C**, Xiao D, Qi H, Xiao X. (2018) Paternal hyperglycemia induces transgenerational inheritance of susceptibility to hepatic steatosis in rats involving altered methylation on Ppara α

- promoter. *Biochim Biophys Acta Mol Basis Dis*. 2019 Jan;1865(1):147-160. doi: 10.1016/j.bbadis.2018.10.040. Epub 2018 Nov 4.
76. Yang Q, Xu J, Ma Q, Liu Z, Sudhakar V, Cao Y, Wang L, Zeng X, Zhou Y, Zhang M, Xu Y, Wang Y, Weintraub NL, Zhang C, Fukai T, **Wu C**, Huang L, Han Z, Wang T, Fulton DJ, Hong M, Huo Y. (2018) PRKAA1/AMPK α 1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis. *Nat Commun*. 2018 Nov 7;9(1):4667. doi: 10.1038/s41467-018-07132-x.
77. Yan H, Yang W, Zhou F, Li X, Pan Q, Shen Z, Han G, Newell-Fugate A, Tian Y, Majeti R, Liu W, Xu Y, **Wu C**, Allred K, Allred C, Sun Y, Guo S. (2018) Estrogen Improves Insulin Sensitivity and Suppresses Gluconeogenesis via the Transcription Factor Foxo1. *Diabetes*. 2019 Feb;68(2):291-304. doi: 10.2337/db18-0638. Epub 2018 Nov 28.
78. Hu X, Zhang Q, Zeng T, Zhang JY, Min J, Tian SH, Huang HT, Peng M, Zhang N, Li MJ, Wan Q, Xiao F, Chen Y, **Wu C**, Chen LL. (2018) Not performing an OGTT results in underdiagnosis, inadequate risk assessment and probable cost increases of (pre)diabetes in Han Chinese over 40 years: a population based prospective cohort study. *Endocr Connect*. 2018 Dec 1. pii: EC-18-0372. doi: 10.1530/EC-18-0372. [Epub ahead of print]
79. Summerfield M, Zhou Y, Zhou T, **Wu C**, Alpini G, Zhang KK, Xie L. (2018) A long-term maternal diet transition from high-fat diet to normal fat diet during pre-pregnancy avoids adipose tissue inflammation in next generation. *PLoS One*. 2018 Dec 18;13(12):e0209053. doi: 10.1371/journal.pone.0209053. eCollection 2018.
80. Zhang M, Zeng X, Yang Q, Xu J, Liu Z, Zhou Y, Cao Y, Zhang X, An X, Xu Y, Huang L, Han Z, Wang T, **Wu C**, Fulton DJ, Weintraub NL, Hong M, Huo Y. (2018) Ablation of myeloid adenosine kinase epigenetically suppresses atherosclerosis in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol*, 2018 Dec;38(12):2780-2792. doi: 10.1161/ATVBAHA.118.311806.
81. Ravisankar S, Agah S, Kim H, Talcott S, **Wu C**, Awika J. (2019) Combined cereal and pulse flavonoids show enhanced bioavailability by downregulating phase II metabolism and ABC membrane transporter function in Caco-2 model. *Food Chem*. 2019 May 1;279:88-97. doi: 10.1016/j.foodchem.2018.12.006. Epub 2018 Dec 6.
82. Wan Y, Ceci L, Wu N, Zhou T, Chen L, Venter J, Francis H, Bernuzzi F, Invernizzi P, Kyritsi K, Baker P, Huang Q, **Wu C**, Sybenga A, Alpini G, Meng F, Glaser S. (2019) Knockout of α -calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes. *Lab Invest*. 2019 Jun;99(6):764-776. doi: 10.1038/s41374-018-0178-5. Epub 2019 Jan 30.
83. McDaniel K, Wu N, Zhou T, Huang L, Sato K, Venter J, Ceci L, Chen D, Ramos-Lorenzo S, Invernizzi P, Bernuzzi F, **Wu C**, Francis H, Glaser S, Alpini G, Meng F. (2019) Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 knockout mice via let-7 microRNA. *Hepatology*. 2019 Jun;69(6):2562-2578. doi: 10.1002/hep.30542. Epub 2019 Apr 12.
84. Chen L, Zhou T, Wu N, O'Brien A, Venter J, Ceci L, Kyritsi K, Onori P, Gaudio E, Sybenga A, Xie L, **Wu C**, Fabris L, Invernizzi P, Zawieja D, Liangpunsakul S, Meng F, Francis H, Alpini G, Huang Q, Glaser S. (2019) Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased

- melatonin synthesis. *Biochim Biophys Acta Mol Basis Dis*. 2019 Jun 1;1865(6):1525-1539. doi: 10.1016/j.bbadis.2019.03.002. Epub 2019 Mar 16.
85. Zhou Y, Zeng X, Li G, Yang Q, Xu J, Zhang M, Mao X, Cao Y, Wang L, Xu Y, Wang Y, Zhang Y, Xu Z, **Wu C**, Chen JF, Hoda MN, Liu Z, Hong M, Huo Y. (2019) Inactivation of endothelial adenosine receptor 2A protects mice from cerebral ischemia-induced brain injury. *Br J Pharmacol*. 2019 Jul;176(13):2250-2263. doi: 10.1111/bph.14673. Epub 2019 May 21.
86. Yang W, Yan H, Pan Q, Shen Z, Zhou F, **Wu C**, Sun Y, Guo S. (2019) Glucagon regulates hepatic mitochondrial function and biogenesis through Foxo1. *J Endocrinol*. 2019 Jun 1;241(3):265-278. doi: 10.1530/JOE-19-0081.
87. Ahmed Abdalhamid Osman M, Sun YJ, Li RJ, Lin H, Zeng DM, Chen XY, He D, Feng HW, Yang Z, Wang J, **Wu C**, Cui M, Sun JP, Huo Y, Yu X. (2019) Deletion of pancreatic β -cell adenosine kinase improves glucose homeostasis in young mice and ameliorates streptozotocin-induced hyperglycaemia. *J Cell Mol Med*. 2019 Jul;23(7):4653-4665. doi: 10.1111/jcmm.14216. Epub 2019 May 1.
88. Xu J, Yang Q, Zhang X, Liu Z, Cao Y, Wang L, Zhou Y, Zeng X, Ma Q, Xu Y, Wang Y, Huang L, Han Z, Wang T, Stepp D, Bagi Z, **Wu C**, Hong M, Huo Y. Endothelial adenosine kinase deficiency ameliorates diet-induced insulin resistance. *J Endocrinol*. 2019 Aug;242(2):159-172. doi: 10.1530/JOE-19-0126.
89. Cao Y, Zhang X, Wang L, Yang Q, Ma Q, Xu J, Wang J, Kovacs L, Ayon RJ, Liu Z, Zhang M, Zhou Y, Zeng X, Xu Y, Wang Y, Fulton DJ, Weintraub NL, Lucas R, Dong Z, Yuan JX, Sullivan JC, Meadows L, Barman SA, **Wu C**, Quan J, Hong M, Su Y, Huo Y. PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension. *Proc Natl Acad Sci U S A*. 2019 Jul 2;116(27):13394-13403. doi: 10.1073/pnas.1821401116. Epub 2019 Jun 18.
90. Zhou J (**PhD student**), Li H, Cai Y (**visiting PhD student**), Ma L (**visiting PhD student**), Mathews D (**MS student**), Lu B (**visiting scholar**), Zhu B (**visiting scholar**), Chen Y, Qian X, Xiao X, Li Q, Guo S, Huo Y, Zhao L, Tian Y, Li Q, **Wu C (corresponding author)**. (2019) Mice lacking adenosine 2A receptor reveal increased severity of MCD-induced NASH. *J Endocrinol*. 2019 Sep 1:JOE-19-0198.R1. doi: 10.1530/JOE-19-0198. Online ahead of print.
91. Zhou T, Kyritsi K, Wu N, Francis H, Yang Z, Chen L, O'Brien A, Kennedy L, Ceci L, Meadows V, Kusumanchi P, Wu C, Baiocchi L, Skill NJ, Saxena R, Sybenga A, Xie L, Liangpunsakul S, Meng F, Alpini G, Glaser S. (2019) Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2^{-/-} mouse model of primary sclerosing cholangitis (PSC). *EBioMedicine*. 2019 Oct;48:130-142. doi: 10.1016/j.ebiom.2019.09.013. Epub 2019 Sep 12.
92. Kyritsi K, Chen L, O'Brien A, Francis H, Hein TW, Venter J, Wu N, Ceci L, Zhou T, Zawieja D, Gashev AA, Meng F, Invernizzi P, Fabris L, **Wu C**, Skill NJ, Saxena R, Liangpunsakul S, Alpini G, Glaser S. (2020) Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. *Hepatology*. 2020 Mar;71(3):990-1008. doi: 10.1002/hep.30880. Epub 2019 Oct 18.
93. Shi G, Liu D, Zhou B, Liu Y, Hao B, Yu S, Wu L, Wang M, Song Z, **Wu C**, Zhu J, Qian X. (2019) Ginsenoside Rb1 alleviates ox-LDL-induced vascular endothelium

- senescence via the SIRT1/Beclin-1/autophagy axis. *J Cardiovasc Pharmacol*. 2020 Feb;75(2):155-167. doi: 10.1097/FJC.0000000000000775.
94. Wang X, Rao H, Zhao J, Wee A, Li X, Fei R, Huang R, **Wu C**, Liu F, Wei L. (2019) STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease. *Lab Invest*. 2020 Apr;100(4):542-552. doi: 10.1038/s41374-019-0342-6. Epub 2019 Nov 19.
 95. Ma L (**visiting PhD student**), Li H, Hu J, Zheng J, Zhou J (**PhD student**), Botchlett R, Matthews D (**MS student**), Zeng T, Chen L, Xiao X, Athrey G, Threadgill D, Li Q, Glaser S, Francis H, Meng F, Li Q, A, Alpini G, **Wu C (corresponding author)**. (2020) Indole alleviates diet-induced hepatic steatosis and inflammation in a manner involving myeloid cell PFKFB3. *Hepatology*, 2020 Oct;72(4):1191-1203. doi: 10.1002/hep.31115. Epub 2020 Jun 29.
 96. Deng M, Qu F, Chen L, Liu C, Zhang M, Ren F, Guo H, Zhang H, Ge S, **Wu C (co-corresponding author)**, Zhao L. (2020) SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. *J Endocrinol*. 2020 Jun;245(3):425-437. doi: 10.1530/JOE-20-0018.
 97. Kyritsi K, Francis H, Zhou T, Ceci L, Wu N, Yhang Z, Meng F, Chen L, Baiocchi L, Kundu D, Kennedy L, Liangpunsakul S, **Wu C**, Glaser S, Alpini G. (2020) Downregulation of p16 decreases biliary damage and liver fibrosis in the Mdr2^{-/-} mouse model of primary sclerosing cholangitis. *Gene Expr*. 2020 May 11. doi: 10.3727/105221620X15889714507961. Online ahead of print.
 98. Ceci L, Francis H, Zhou T, Giang T, Yang Z, Meng F, Wu N, Kennedy L, Kyritsi K, Meadows V, **Wu C**, Liangpunsakul S, Franchitto A, Sybenga A, Ekser B, Mancinelli R, Onori P, Gaudio E, Glaser S, Alpini G. (2020) Knockout of the Tachykinin Receptor 1 in the Mdr2^{-/-} Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis. *Am J Pathol*. 2020 Jul 23:S0002-9440(20)30341-2. doi: 10.1016/j.ajpath.2020.07.007. Online ahead of print.
 99. Hu R, Li X, Peng C, Gao R, Ma L, Hu J, Luo T, Qing H, Wang Y, Ge Q, Wang Z, Wu C, Xiao X, Yang J, Young MJ, Li Q, Yang S. (2020) miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes. *BMJ Open Diabetes Res Care*. 2020 Jul;8(1):e001101. doi: 10.1136/bmjdr-2019-001101.
 100. Guo X (**PhD student**), Zhu B (**Visiting Scholar**), Xu H (**PhD student**), Li H, Jiang B, Wang Y, Zheng B, Glaser S, Alpini G, and **Wu C (corresponding author)**. (2020) Adoptive transfer of *Pfkfb3*-disrupted hematopoietic cells to wild-type mice exacerbates diet-induced hepatic steatosis and inflammation. *Liver Res*, 2020,4:136-144
 101. Ke SY, Yu SJ, Liu DH, Shi GY, Wang M, Zhou B, Wu L, Song ZM, Zhu JM, **Wu CD**, Qian XX. (2021) Ginsenoside Rb1 Protects Human Umbilical Vein Endothelial Cells against High Glucose-Induced Mitochondria-Related Apoptosis through Activating SIRT3 Signalling Pathway. *Chin J Integr Med*. 2021 May;27(5):336-344. doi: 10.1007/s11655-020-3478-8. Epub 2021 Jan 9. PMID: 33420900
 102. Zhu B (**Visiting Scholar**), Guo X (**PhD student**), Xu H (**PhD student**), Jiang B, Li H, Wang Y, Yin Q, Zhou T, Cai JJ, Glaser S, Meng F, Francis H, Alpini G, and **Wu C (corresponding author)**. (2021) Adipose Tissue Inflammation and Systemic

- Insulin Resistance in Mice with Diet-induced Obesity Is possibly Associated with Disruption of PFKFB3 in Hematopoietic Cells. *Lab Invest*, 2021 Mar;101(3):328-340. doi: 10.1038/s41374-020-00523-z. Epub 2021 Jan 18. PMID: 33462362
103. Chen L, Zhou T, White T, O'Brien A, Chakraborty S, Liangpunsakul S, Yang Z, Kennedy L, Saxena R, **Wu C**, Meng F, Huang Q, Francis H, Alpini G, Glaser S. (2020) The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis. *Hepatology*. 2021 Jun;73(6):2411-2428. doi: 10.1002/hep.31545. Epub 2021 May 22. PMID: 32964473
104. Xu H (**PhD student**), Zhu B (**Visiting Scholar**), Li H, Jiang B, Li H, Wang Y, Yin Q, Cai JJ, Glaser S, Francis H, Alpini G, and **Wu C (corresponding author)**. (2021) Adipocyte inducible 6-phosphofructo-2-kinase suppresses adipose tissue inflammation and promotes macrophage anti-inflammatory activation. *J Nutr Biochem*, 2021 Sep;95:108764. doi: 10.1016/j.jnutbio.2021.108764. Epub 2021 May 6. PMID: 33964465
105. Cao X, Mao M, Diao J, Hou Y, Su H, Gan Y, Li J, Tong X, **Wu C**, Zuo Z, Xiao X. (2021) Ectopic Overexpression of PPAR γ 2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes. *Front Pharmacol*, 2021 Jul 7;12:683156. doi: 10.3389/fphar.2021.683156. eCollection 2021. PMID: 34305596
106. Chen L, Wu N, Kennedy L, Francis H, Ceci L, Zhou T, Samala N, Kyritsi K, Wu C, Sybenga A, Ekser B, Dar W, Atkins C, Meadows V, Glaser S, Alpini G. (2021) Inhibition of secretin/secretin receptor axis ameliorates non-alcoholic fatty liver disease phenotypes. *Hepatology*. 2021 Oct;74(4):1845-1863. doi: 10.1002/hep.31871. Epub 2021 Jul 29. PMID: 33928675
107. Matthews DR (**MS student**), Li H, Zhou J H (**PhD student**), Li Q, Glaser S, Francis H, Alpini G, **Wu C (corresponding author)**. (2021) Methionine- and Choline-deficient Diet-induced Non-alcoholic Steatohepatitis Is Associated with Increased Intestinal Inflammation. *Am J Pathol*. 2021 Oct;191(10):1743-1753. doi: 10.1016/j.ajpath.2021.06.010. Epub 2021 Jul 7. PMID: 34242656
108. Lin S, Li Y, Wang D, Huang C, Marino D, Bollt O, **Wu C**, Taylor MD, Li W, DeNicola GM, Hao J, Singh PK, Yang S. (2021) Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression. *Cancer Lett*, 2021 Oct 10;518:230-242. doi: 10.1016/j.canlet.2021.07.025. Epub 2021 Jul 22. PMID: 34303764
109. Lin X, Zhang Y, He X, Chen Y, Chen N, Liu J, Wang M, Li Y, Yang H, Fan L, Hou Y, Li J, **Wu C**, Qi H, Zhang H, Xiao X. (2021) The choline metabolite TMAO inhibits NETosis and promotes placental development in GDM of humans and mice. *Diabetes*. 2021 Oct;70(10):2250-2263. doi: 10.2337/db21-0188. Epub 2021 Jul 27. PMID: 34315726
110. O'Brien A, Zhou T, White T, Medford A, Chen L, Kyritsi K, Wu N, Childs J, Stiles D, Ceci L, Chakraborty S, Ekser B, Baiocchi L, Carpino G, Gaudio E, **Wu C**, Kennedy L, Francis H, Alpini G, Glaser S. (2022) FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2 $^{-/-}$ Mouse Model of Primary Sclerosing Cholangitis. *Hepatol Commun* 2022 Jul;6(7):1574-1588. doi: 10.1002/hep4.1909. Epub 2022 Mar 10. PMID: 35271760

111. Zhu B (**Visiting scholar**), Li H, Lu B (**Visiting scholar**), Guo X, Wu C, Wang F, Li Q, Xie L, Glaser S, Francis H, Alpini G, **Wu C (corresponding author)**. (2022) Indole supplementation ameliorates MCD-induced NASH in mice. *J Nutr Biochem* 2022 Sep;107:109041. doi: 10.1016/j.jnutbio.2022.109041. Epub 2022 May 11. PMID: 35568098
112. He L, Wang X, Ding Z, Liu L, Cheng H, Bily D, **Wu C**, Zhang K, Xie L. (2022) Deleting Gata4 in hepatocytes promoted the progression of NAFLD via increasing steatosis and apoptosis, and desensitizing insulin signaling. *J Nutr Biochem* 2022 Sep 20:109157. doi: 10.1016/j.jnutbio.2022.109157. Online ahead of print. PMID: 36150682
113. Li H, Zheng J, Xu Q, Yang Y, Zhou J, Guo X, Cai Y, Cai JJ, Xie L, Awika J, Han X, Li Q, Kennedy L, Francis H, Glaser S, Huo Y, Alpini G, **Wu C (corresponding author)**. (2022) Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation. *Gastroenterology* 2022 Sep 28:S0016-5085(22)01085-X. doi: 10.1053/j.gastro.2022.09.027. Online ahead of print. PMID: 36181835
114. Liu L, Zhou Y, Liu Z, Li J, Hu L, He L, Gao G, Kidd B, Walsh A, Jiang R, **Wu C**, Zhang K, Xie L. (2023) Osr1 regulates macrophage-mediated liver inflammation in non-alcoholic fatty liver disease progression. *Cell Mol Gastroenterol Hepatol*. 2022 Dec 26:S2352-345X(22)00261-2. doi: 10.1016/j.jcmgh.2022.12.010. Online ahead of print. PMID: 36581078
115. Wan Y, Zhou T, Slevin E, Koyama S, Li X, Harrison K, Li T, Zhou B, Lorenzo SR, Zhang Y, Xu W, Klaunig JE, **Wu C**, Shetty AK, Huang CK, Meng F. (2023) Liver-specific deletion of microRNA-34a alleviates ductular reaction and liver fibrosis during experimental cholestasis. *FASEB J*. 2023 Feb;37(2):e22731. doi: 10.1096/fj.202201453R. PMID: 36583714
116. Muthyala S, Chapkin RS, **Wu C**, Wu CS. (2023) Ghrelin Alleviates Experimental Ulcerative Colitis in Old Mice and Modulates Colonocyte Metabolism via PPAR γ Pathway. *Int J Mol Sci*. 2022 Dec 29;24(1):565. doi: 10.3390/ijms24010565. PMID: 36614012
117. Kyritsi K, Wu N, Zhou T, Carpino G, Baiocchi L, Kennedy L, Chen L, Ceci L, Meyer AA, Barupala N, Franchitto A, Onori P, Eksler B, Gaudio E, **Wu C**, Marakovits C, Chakraborty S, Francis H, Glaser S, Alpini G. (2023) Knockout of secretin ameliorates biliary and liver phenotypes during alcohol-induced hepatotoxicity. *Cell Biosci*. 2023 Jan 9;13(1):5. doi: 10.1186/s13578-022-00945-w. PMID: 36624475
118. Wu N, Zhou T, Carpino G, Baiocchi L, Kyritsi K, Kennedy L, Ceci L, Chen L, **Wu C**, Kundu D, Barupala N, Franchitto A, Onori P, Eksler B, Gaudio E, Francis H, Glaser S, Alpini G. (2023) Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2 $^{-/-}$ mice. *Hepatology*. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310. Online ahead of print. PMID: 36799446
119. Kundu D, Kennedy L, Zhou T, Eksler B, Meadows V, Sybenga A, Kyritsi K, Chen L, Ceci L, Wu N, **Wu C**, Glaser S, Carpino G, Onori P, Gaudio E, Alpini G, Francis H. (2023) p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling. *Hepatology*. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307. Online ahead of print. PMID: 36799449

120. Wan Y, Slevin E, Koyama S, Huang CK, Shetty AK, Li X, Harrison K, Li T, Zhou B, Lorenzo SR, Zhang Y, Salinas JM, Xu W, Klaunig JE, **Wu C**, Tsukamoto H, Meng F. (2023) miR-34a regulates macrophage-associated inflammation and angiogenesis in alcohol-induced liver injury. *Hepatol Commun*. 2023 Apr 4;7(4):e0089. doi: 10.1097/HC9.0000000000000089. eCollection 2023 Apr 1. PMID: 37026704
121. You Y, Huang Y, Wang X, Ni H, Ma Q, Ran H, Cai J, Lin X, Luo T, **Wu C**, Xiao X, Ma L. (2024) Ketogenic diet time-dependently prevents NAFLD through upregulating the expression of antioxidant protein metallothionein-2. *Clin Nutr* 2024 Jun;43(6):1475-1487. doi: 10.1016/j.clnu.2024.04.029. Epub 2024 Apr 22. PMID: 38723301
122. Guo X, Li H, Zhu B, Wang X, Xu Q, Aquino E, Koo M, Li Q, Cai J, Glaser S, **Wu C** (corresponding author). (2024) HFD feeding for seven months abolishes STING disruption-driven but not female sex-based protection against hepatic steatosis and inflammation in mice. *J Nutr Biochem* 2025 Jan;135:109770. doi: 10.1016/j.jnutbio.2024.109770. Epub 2024 Sep 14. PMID: 39284534

Abstracts

1. **Wu C**, Okar D.A., Newgard C.B., and Lange A.J. Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in mouse liver leads to suppression of hepatic glucose production and lowered blood glucose. *Diabetes* 2000,49(suppl 1):A291.
2. Choi I-Y. , **Wu C**, Okar D.A., Lange A.J and Grutter R. Assessment of hepatic carbohydrate metabolism in vivo by 3D-localized ¹³C NMR: The role of fructose-2,6-bisphosphate in regulation of glucose fluxes in mice. *Proc Int Soc Magn Reson Med* 2001,9:206.
3. Herrera A, **Wu C**, Lange A.J., and Herrera J. Regulation of hepatic levels of HNF-1/HNF-4 by fructose-2, 6-bisphosphate. *Diabetes* 2001,50(suppl 2):A409.
4. **Wu C**, Okar D.A., Peng, L-J., and Lange A.J. Decreasing fructose-2,6-bisphosphate leads to diabetic phenotype in normal mice. *Diabetes* 2002,51(suppl 2):A319.
5. **Wu C**, Okar D.A., Peng, L-J., and Lange A.J. Effect of fructose-2,6-bisphosphate level on Akt phosphorylation. *Diabetes* 2002,51(suppl 2):A452-453.
6. Kang J., **Wu C**, Peng L.J., and Lange A.J. The interactions between fructose-2,6-bisphosphate and hepatic glucokinase in maintaining blood glucose homeostasis. *Diabetes* 2003,52(Suppl 1): A547.
7. **Wu C**, L.J. Peng, Okar D.A., and Lange A.J. Reduction of adiposity by increasing fructose-2, 6-bisphosphate concentration in obese mice. *Diabetes* 2003,52(suppl 1):A391.
8. **Wu C**, Wu P., Peng L-J., Okar D.A., Harris R.A., and Lange A.J. Increasing hepatic fructose-2,6-bisphosphate content alters PDK-4 expression in extra-hepatic tissues. *Diabetes* 2003,52(suppl 1):A536.
9. Donthi R., Fan T., **Wu C**, Lange A.J., and Epstein P. Over-Expression of kinase deficient 6-phosphofructo-2-kinase/fructose2,6-bisphosphate alters cardiac metabolism and induces mild hypertrophy. *Diabetes* 2003,52(suppl 1):A117.

Curriculum Vitae: Chaodong Wu, MD, PhD

10. Donthi R., **Wu C.**, McClain D., Lange A.J., Epstein P.N. Cardiac over-expression of kinase deficient PFK-2 induces insulin resistance, mild hypertrophy and sensitization to ischemia. *FASEB J* 2004,18(S):C167.
11. **Wu C.**, Kang, J., Peng, L.J., Li, H., Hillard, C.J., Lange, A.J. Acceleration of energy expenditure by increasing hepatic glucose metabolism of obese mice. *Diabetes* 2004,53(suppl2):A411.
12. **Wu C.**, Peng L.J., Kang J., Li H., and Lange A.J. Differential effects of fructose-2,6-bisphosphate on liver and skeletal muscle fatty acid oxidation in obese mice. *Diabetes* 2005,54(suppl 1):A360-361.
13. **Wu C.**, Peng L.J., Khan S.A., Kang J., Hillard C.J., and Lange A.J. Alterations of hepatic flux by decreasing fructose-2,6-bisphosphate levels lead to insulin resistance of the liver and whole body. *Diabetes* 2005,54(suppl 1):A378.
14. Khan SA, **Wu C.**, Peng LJ, and Lange AJ. Mapping the fructose-2,6-bisphosphate signaling pathway. *FASEB J*, 2006,20(5):A959-A960 Part 2.
15. **Wu C.**, and Lange A.J. Cooperative regulation of hepatic fuel metabolism: A proteomic study of the effects of fructose-2,6-bisphosphate. *FASEB J*, 2006,20(5):A959.Part 2.

Since appointment as Assistant Professor at TAMU (in April 2007)

16. Guo X. (**PhD student**), Li H., and **Wu C.** (*corresponding author*). A role of PFKFB3/iPFK2 in the regulation of neuronal glycolysis and food intake. *FASEB J*. 2009 23:973.1
17. Guo X. (**PhD student**), Li H., and **Wu C.** (*corresponding author*) A role of PFKFB3/iPFK2 in the regulation of high fat diet-induced inflammation and metabolic responses. *FASEB J*. 2009,23:109.8
18. Thomas, L.N., Guo X. (**PhD student**), **C. Wu**, and Sturino, J.M. Inflammation attenuation by rosiglitazone also affects biomarkers related to host-microbiota interaction. United States National Academy of Sciences Sackler Symposium on Microbes and Health (Irvine, CA). 2009 Awarded, Graduate Student Registration Grant.
19. Li H., Guo X. (**PhD student**), Thomas L.N., Sturino J.M., and **Wu C.** (*corresponding author*) Involvement of PFKFB3/iPFK2 in the suppressive effect of rosiglitazone on diet-induced intestine inflammatory response. *FASEB J*. 2010,24:341.5
20. Guo X. (**PhD student**), Li H., and **Wu C.** (*corresponding author*) PFKFB3/iPFK2 links nutrient metabolism and overnutrition-associated adipocyte inflammatory response through controlling oxidative stress. *FASEB J*. 2010 24:543.2
21. Guo X. (**PhD student**), Xu K., Li H., Zhang W., Wang H., Zhang J., Huo Y., Chen Y.E., and **Wu C.** (*corresponding author*) Inducible 6-phosphofructo-2-kinase is involved in the anti-diabetic effect of rosiglitazone in mice. *Diabetes*, 2010,59(S1):A393
22. Guo X. (**PhD student**), Li H., Lu F., and **Wu C.** (*corresponding author*) Adipocyte PFKFB3 overexpression protects mice from diet-induced adipose tissue inflammation and systemic insulin resistance. *FASEB J*. 2011,25:337.8

23. Halim V. (**MS student**), Guo X. (**PhD student**), Li H., and **Wu C.** (*corresponding author*). A novel mechanism for the insulin-sensitizing effect of leucine in adipocytes. *FASEB J.* 2011,25:351.2
24. Guo X. (**PhD student**), Li H., Xu H. (**PhD student**), Meng C. (**PhD student**), Zhuang G., Zhou B., Lu F. **Wu C.** (*corresponding author*). A critical role for adipose tissue in regulating diet-induced liver inflammatory response. *Diabetes*, 2011,60(S1):
25. Zhuang G, Meng C, Guo X (**PhD student**), Xu H (**PhD student**), Wang G, Li H, Shi L, **Wu C.**, and Zhou B. MicroRNA-223 regulates macrophage polarization and protects mice from diet-induced insulin resistance and adipose tissue inflammation. *Circulation*, 2011;124:A17934
26. Guo X. (**PhD student**), Li H., Xu H. (**PhD student**), Meng C, and **Wu C.** (*corresponding author*). Palmitoleate supplementation dissociates liver inflammatory response from hepatic steatosis in mice. *FASEB J.* 2012,26:34.6
27. Xu H. (**PhD student**), Guo X. (**PhD student**), Li H., Woo S.L. (**MS student**), and **Wu C.** (*corresponding author*). A role for palmitoleate in regulating macrophage activation. *FASEB J.* 2013,27:865.9
28. Botchlett R. (**PhD student**), Woo SL (**PhD student**), Xu H (**PhD student**), Li H., **Wu C.**, and Lawler J. Effects of a high fat diet and Metformin on skeletal muscle membrane proteins and fiber size in young mice. *FASEB J.* 2013,27:ib295.

Since promotion to Associate Professor (in Sept 2013)

29. Xu H. (**PhD student**), Guo X (**Postdoc**), Li H., Woo S.L. (**MS student**), and **Wu C.** (*corresponding author*). Metabolic regulation of adipose tissue inflammation and systemic insulin sensitivity: a role for PFKFB3 in macrophage polarization. *Circulation*, 2013;128:A18901
30. Xu H. (**PhD student**), Li H., Woo S.L. (**MS student**), Guo X (**Postdoc**), Guo T., Qi T., and **Wu C.** (*corresponding author*). Myeloid cell-specific Circadian Clock Disruption Exacerbates Diet-induced Obesity and Inflammation. *Energy Balance & Cancer* 2014, MD Anderson Cancer Center. Poster presentation
31. Woo S.L. (**PhD student**), Xu H. (**PhD student**), Li H., Guo X. (**Postdoc**), Guo T. (**MS student**), Qi T. (**MS student**), Huo Y., and **Wu C.** (*corresponding author*). Metformin ameliorates diet-induced hepatic steatosis and inflammation without altering adipose phenotype. *FASEB J.* 2014,28:37.1 oral presentation
32. Guo X (**Postdoc**), Guo T (**MS student**), Li H, Pei Y (**PhD student**), Xu H (**PhD student**), Hu X (**Postdoc**), Zhao Y (**Postdoc**), Zhao J, and **Wu C.** (*corresponding author*). Temporal effects of peroxisome proliferator-activated receptor γ (PPAR γ) activation on macrophage inflammatory responses. *FASEB J.* 2014,28:1037.3 poster presentation
33. Botchlett R (**PhD student**), Hu X (**Postdoc**), Qi T (**MS student**), Zhao J (**visiting PhD student**), Li H, and **Wu C.** (*corresponding author*). Macronutrients Differentially Regulate PFKFB3 Expression and Increase Inflammation in Intestinal Epithelial Cells. *FASEB J.* 2015,29:405.1
34. Wang Y, Xu Y, Zeng X, Zhou Y, Liu Z, **Wu C.**, Li Q, and Huo Y. Intracellular adenosine suppresses Vsmc phenotypic switch through Klf4 gene methylation. *Circulation*, 2015; 132: A14743

35. Xu Y, Yan S, Wang Y, An X, Li Q, **Wu C**, and Huo Y. Endothelial Intracellular Adenosine Epigenetically Regulates Angiogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2015; 35: A10
36. Cai Y (**Visiting PhD student**), Zheng J (**Postdoc**), Guo X (**Postdoc**), Li H, Pei Y (**PhD student**), Xu H (**PhD student**), Botchlett R. (**PhD student**), Woo SL (**PhD student**), Chen G (**Postdoc**), Huo Y, and **Wu C** (*corresponding author*). Adenosine 2A Receptor Deficiency Exacerbates NAFLD in both HFD-fed and MCD-fed Mice. *25th Conference of the Asian Pacific Association for the Study of the Liver* (APASL 2016 Tokyo)
37. Cai Y (**visiting PhD student**), Zheng J (**Postdoc**), Guo X (**Postdoc**), Li H, Pei Y (**PhD student**), Botchlett R. (**PhD student**), Woo SL (**PhD student**), Liu M (**Postdoc**), Cheng G (**Postdoc**), Huo Y, and **Wu C** (*corresponding author*). Exacerbation of NAFLD in both HFD-fed Mice and MCD-fed Mice by Adenosine 2A Receptor Deficiency. *FASEB J.* 2016,30:431.7
38. Woo SL (**PhD student**), Guo T (**MS student**), Guo X (**Postdoc**), Li H, Zheng J (**Postdoc**), Botchlett R (**PhD student**), Cai Y (**visiting PhD student**), Li X, Li Q, Xiao X, Huo Y, and **Wu C** (*corresponding author*). Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Obesity Mice Independent of AMPK. *FASEB J.* 2016,30:126.5 Selected for American Society for Nutrition Emerging Leaders in Nutrition Science Poster Competition.
39. Pei Y (**PhD student**), Cai Y (**visiting PhD student**), Woo SL (**PhD student**), Liu M (**Postdoc**), Huo Y, and **Wu C** (*corresponding author*). Dietary effects on A_{2A}R expression in liver and adipose tissues: A role for A_{2A}R in protecting against inflammation and insulin resistance in obesity. *FASEB J.* 2017,31:
40. Cai Y (**Visiting PhD student**), Li H, Liu M (**Postdoc**), Pei Y (**PhD student**), Woo SL (**PhD student**), Huo Y, and **Wu C** (*corresponding author*). Disruption of A_{2A}R exacerbates aspects of diet-induced NAFLD and increases hepatic SREBP1c expression under fasted states. *Diabetes*, 2017,66: Suppl 1,A509.
41. Luo X (**visiting PhD student**), Li H, Pei Y (**PhD student**), Zhou J (**PhD student**), Huang W (**visiting PhD student**), Francis H, Meng F, Alpini G, and **Wu C** (*corresponding author*). Increased Liver TBK1-IRF3 Signaling Is Associated with Diet-induced Non-alcoholic Fatty Liver Disease in Mice. *2017 The Kutscher Digestive Disease Research Center Symposium*, Temple, Texas
42. Zhou J (**PhD student**), Li H, Pei Y (**PhD student**), Lou X (**visiting PhD student**), Huang W (**visiting PhD student**), and **Wu C** (*corresponding author*). Adenosine kinase: nutritional regulation and role in diet-induced NAFLD. *2017 The Kutscher Digestive Disease Research Center Symposium*, Temple, Texas
43. Zhou J (**PhD student**), Li H, Lou X (**visiting PhD student**), Ma L (**visiting PhD student**), and **Wu C** (*corresponding author*). A Role for Macrophage Adenosine 2A Receptor in Diet-induced non-alcoholic Fatty Liver Disease. *Diabetes*, 2018,Suppl.
44. Zhou J (**PhD student**), Li H, Luo X (**visiting PhD student**), Ma L (**visiting PhD student**), and **Wu C** (*corresponding author*). A Role for Macrophage Adenosine 2A Receptor in Diet-induced non-alcoholic Fatty Liver Disease. *2018 Texas A&M Nutrition Obesity Research Symposium*, College Station, Texas
45. Ma L (**visiting PhD student**), Li H, Zhou J (**PhD student**), Luo X (**visiting PhD student**), and **Wu C** (*corresponding author*). Myeloid Cell-specific PFKFB3

- Disruption Exacerbates Diet-induced Non-alcoholic Fatty Liver Disease in Mice. *2018 Texas A&M Nutrition Obesity Research Symposium*, College Station, Texas
46. Matthews DR (**MS student**), Huang W (**visiting PhD student**), Luo X(**visiting PhD student**), Pei Y(**PhD student**), Zhou J (**PhD student**), Li H and **Wu C** (**corresponding author**). Induction of intestinal inflammation in mice by methionine- and choline-deficient diet. *2018 Texas A&M Nutrition Obesity Research Symposium*, College Station, Texas
 47. Mahmood A(**Visiting PhD student**), Faisal MN, Khaliq T, Khan JA, Muhammad F, Muzaffar H, **Wu C** (**corresponding author**). Progression of High Fat Diet Induced Obesity and Metabolic Stress in Wistar Rats. *2018 Texas A&M Nutrition Obesity Research Symposium*, College Station, Texas

Since last promotion to Professor (in Sept 2018)

48. Li H, Ma L(**visiting PhD student**), Zhou J (**PhD student**), Luo X (**visiting PhD student**), Francis H, Glaser S, Meng F, Alpini G, and **Wu C** (**corresponding author**). Disruption of Myeloid Cell-specific PFKFB3 Exacerbates Diet-induced Hepatic Steatosis and Inflammation in Mice. 2018 AASLD Scientific Meeting, San Francisco, CA
49. Li H, Ma L (**visiting PhD student**), Hu J, and **Wu C** (**corresponding author**). A Potential Role for Microbiota Metabolite Indole in Protecting against Diet-induced Hepatic Steatosis and Inflammation. *2019 Alcoholic and Nonalcoholic Steatohepatitis: Pathogenesis and Mechanisms of Liver Injury. Joint NIAAA-NIDDK Research Workshop. Washington DC*
50. Zhu B (**visiting scholar**), Li H, and **Wu C** (**corresponding author**). Sting In Hematopoietic Cells Promotes Obesity-associated Adipose Tissue Inflammation And Systemic Insulin Resistance In Mice. 2020 The 80th Scientific Sessions of American Diabetes Association, Chicago, IL, USA (virtual meeting)
51. Zhu B (**visiting scholar**), Li H, and **Wu C** (**corresponding author**). Sting In Hematopoietic Cells Promotes Obesity-associated Adipose Tissue Inflammation And Systemic Insulin Resistance In Mice. 2020 The 80th Scientific Sessions of American Diabetes Association, Chicago, IL, USA (virtual meeting)
52. Li H and **Wu C** (**corresponding author**). Indole Supplementation Ameliorates MCD-induced NASH in Mice. Chinese American Diabetes Association - South Winter Retreat, Saturday, December 11, 2021, Hilton College Station & Conference Center
53. Guo X, Li H and **Wu C** (**corresponding author**). STING disruption protects obesity-associated adipose tissue inflammation and systemic insulin resistance in mice. Chinese American Diabetes Association - South Winter Retreat, Saturday, December 11, 2021, Hilton College Station & Conference Center
54. Wu, N., Zhou, T., Carpino, G., Meyer, A.A., Ceci, L., Zhang, W., Kyritsi, K., Franchitto, A., Chen, L., Kundu, D. and Ekser, B., Wilson A., Baiocchi L., **Wu C.**, Onori P., Chakraborty S., Gaudio E., Meadows V., Francis H., Alpini G., and Glaser S., 2021, October. KNOCKOUT OF BILIARY NEUROKININ 1 RECEPTOR (NK1R) AMELIORATES LIVER PHENOTYPES IN ALCOHOL ASSOCIATED LIVER DISEASE (ALD). In *HEPATOLOGY* (Vol. 74, pp. 226A-226A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.

55. Zhou, T., Wu, N., Carpino, G., Kennedy, L., Meyer, A.A., Ceci, L., Sato, K., Kyritsi, K., Franchitto, A., Chen, L. and Gaudio, E., **Wu C.**, Meadows V., Francis H., Glaser S., and Alpini G. 2021, October. KNOCKOUT OF SECRETIN RECEPTOR (SR) AMELIORATES LIVER PHENOTYPES IN A MOUSE MODEL OF ALCOHOL ASSOCIATED LIVER DISEASE (ALD). In HEPATOLOGY (Vol. 74, pp. 226A-227A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
56. Ceci, L., Carpino, G., Kennedy, L., Wu, N., Chen, L., Kyritsi, K., Zhou, T., Ekser, B., Zhang, W., Onori, P. and Franchitto, A., Mancinelli R., **Wu C.**, Gaudio E., Meadows V., Francis H., Glaser S., and Alpini G. 2021, October. MELATONIN BINDS MT1 TO IMPROVE THE PHENOTYPES OF PRIMARY SCLEROSING CHOLANGITIS (PSC) THROUGH CLOCK GENES/MIR-200B/MASPIN/GST SIGNALING. In HEPATOLOGY (Vol. 74, pp. 273A-274A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
57. Chen, L., Kennedy, L., Kyritsi, K., **Wu, C.**, Ceci, L., Ekser, B., Wu, N., Medford, A., O'Brien, A., Childs, J. and Chakraborty, S., 2021, October. FREE FATTY ACIDS-INDUCED ACTIVATION OF THE ALPHA-CALCITONIN GENE-RELATED PEPTIDE (ACGRP)/CALCITONIN RECEPTOR-LIKE RECEPTOR (CRLR)/RECEPTOR ACTIVITY-MODIFYING PROTEIN 1 (RAMP1) AXIS REGULATES MIR-125B EXPRESSION VIA TLR4 IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). In HEPATOLOGY (Vol. 74, pp. 1063A-1064A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
58. Kyritsi, K., Kennedy, L., Carpino, G., Wu, N., Chen, L., Meyer, A.A., Zhou, T., Franchitto, A., Ceci, L., Zhang, W. and Ekser, B., Onori P., Chakraborty S., Isidan A., Kundu D., **Wu C.**, Gaudio E., Meadows V., Francis H., Alpini G., and Glaser S. 2021, October. INHIBITION OF THE SUBSTANCE P/NEUROKININ RECEPTOR (SP/NK1R) AXIS AMELIORATES LIVER PHENOTYPES IN A MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). In HEPATOLOGY (Vol. 74, pp. 1073A-1073A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
59. Wu, N., Ceci, L., Zhou, T., Francis, H.L., Kennedy, L., Kyritsi, K., Alvaro, D., Carpino, G., **Wu, C.**, Chakraborty, S. and Chen, L., 2021. 233 KNOCKDOWN OF THE MT1 MELATONIN RECEPTOR AMELIORATES THE PHENOTYPES OF THE MDR2-/-MOUSE MODEL OF PRIMARY SCLEROSING CHOLANGITIS (PSC) BY DOWNREGULATION OF ORPHAN GPR50 RECEPTOR-PROMOTED CONSTITUTIVE TGF- β 1 RECEPTOR SIGNALING. *Gastroenterology*, 160(6), pp.S-768.
60. Wan, Y., McDaniel, K.M., Koyama, S., Li, X., Slevin, E., Li, T., Xu, W., Klaunig, J.E., Zhang, Y., **Wu, C.** and Shetty, A., 2022, October. HUMAN LIVER MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES REDUCE LIVER FIBROSIS THROUGH INHIBITION OF p53-MIR-34a AXIS IN ALD. In HEPATOLOGY (Vol. 76, pp. S440-S441). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
61. Koyama, S., Wan, Y., Slevin, E., Xu, W., Huang, C.K., Klaunig, J.E., **Wu, C.**, Shetty, A. and Meng, F., 2022, October. INFLUENCES OF EXPOSURE TO GULF WAR ILLNESS-RELATED CHEMICALS ON GUT DYSBIOSIS AND HEPATIC CLEARANCE OF TRANSLOCATED PATHOBIONTS IN AGING ASSOCIATED

- CHRONIC LIVER INJURIES. In HEPATOLOGY (Vol. 76, pp. S448-S449). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
62. Chen, L., Ceci, L., Kennedy, L., Wu, N., Zhou, T., Kyritsi, K., Meyer, A.A., Ekser, B., Kundu, D., Barupala, N. and Marakovits, C, **Wu C.**, Chakraborty S., Francis H., Glaser S., Alpini G. 2022, October. INHIBITION OF ALPHA-CALCITONIN GENE-RELATED PEPTIDE (. LPHA-CGRP) SIGNALING ATTENUATES METHIONINE- AND CHOLINE-DEFICIENT DIET (MCD)-INDUCED NONALCOHOLIC STEATOHEPATITIS (NASH) PHENOTYPES. In HEPATOLOGY (Vol. 76, pp. S602-S603). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
 63. Kundu, D., Zhou, T., Marakovits, C., Kennedy, L., Chen, L., Kyritsi, K., Wu, N., Ceci, L., **Wu, C.**, Ekser, B. and Alpini, G., 2022, October. BILIARY SENESCENCE REGULATES NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) PHENOTYPES BY E2F1/FOXO1/IGF-1 SIGNALING. In HEPATOLOGY (Vol. 76, pp. S685-S685). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
 64. Wu, N., Ceci, L., Kennedy, L., Chen, L., Kyritsi, K., Barupala, N., Onori, P., Zhou, T., Mancinelli, R.A., Carpino, G. and Gaudio, E., **Wu C.**, Franchitto A., Francis H., Alpini G., and Glaser S. 2022, October. PROLONGED ADMINISTRATION OF MELATONIN AMELIORATES BILIARY AND LIVER PHENOTYPES IN THE FEMALE MDR2-/-MOUSE MODEL OF PRIMARY SCLEROSING CHOLANGITIS. In HEPATOLOGY (Vol. 76, pp. S1016-S1016). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
 65. Slevin, E., Wan, Y., Harrison, K., Li, X., Li, T., Lorenzo, S.R., Zhang, Y., Xu, W., **Wu, C.**, Klaunig, J.E. and Huang, C.K., 2022. Mo1361: HEPATOCYTE SPECIFIC DELETION OF MICRORNA-34A ALLEVIATES DUCTULAR REACTION AND LIVER FIBROSIS DURING EXPERIMENTAL CHOLESTASIS. *Gastroenterology*, 162(7), pp.S-1230.
 66. Guo X (**PhD student**), Li H, and Wu C (**corresponding author**). 2023 Myeloid STING Disruption Alleviates the Deleterious Effect of Myeloid Cell-specific PFKFB3 Deficiency on Diet-induced NAFLD in Mice. Selected for Oral Presentation, *Digestive Disease Week 2023*, Chicago, Illinois, USA
 67. Li H, Guo X (**PhD student**), Xu Q, Cai J, and Wu C (**corresponding author**). 2023 Hepatocyte Promotion of Steatotic Liver Disease Is Associated with Increased Angiogenesis. Poster Presentation, The 5th Gulf Coast Vascular Research Consortium (GVRC) meeting at the George hotel, August 4-5th, 2023, College Station, TX
 68. Guo X (**PhD student**), Minji Koo (**undergraduate**), Li H, and Wu C (**corresponding author**). 2023 Loss of Ovarian Hormones Exacerbates Diet-induced NAFLD. Selected for Poster Presentation, *The Liver Meeting® 2023*, AASLD, Boston, MA, USA
 69. Guo X (**PhD student**), Li H, and Wu C (**corresponding author**). Seven-month HFD Feeding Abolishes the Protective Effect of STING Disruption on Obesity-Associated Hepatic Steatosis, Inflammation, and Insulin Resistance. Selected for Poster Presentation, *American Diabetes Association 2024*, Orlando, FL, USA

Book Chapters

Curriculum Vitae: Chaodong Wu, MD, PhD

1. Baltrusch S., **Wu C.**, Okar D.A., Tiedge M., and Lange A.J. Interaction of GK with the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (6PF2K/F26P₂ase). In *Glucokinase and glycemic disease: From basics to novel therapeutics*. **Frontiers in Diabetes**. Basel, Karger, 2004, 16, pp 262-274.
2. Okar D.A., **Wu C.**, and Lange A.J. Regulation of the regulatory enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. *Adv Enzyme Regul* 2004;44(1):123-154.
3. **Wu C.**, Khan S.A., Peng L.J., and Lange A.J. Roles for fructose-2,6-bisphosphate in the control of fuel metabolism: beyond its allosteric effects on glycolytic and gluconeogenic enzymes. *Adv Enzyme Regul*, 2006, 46: 72-88.

Since promotion to Associate Professor (in Sept 2013)

4. Woo SL (**PhD student**), Guo T (**MS student**), and **Wu C (corresponding author)**. Hepatic lipogenesis: Nutritional control and pathophysiological relevance. (2015) Book chapter, in Hepatic de Novo Lipogenesis and Regulation of Metabolism, Editor: Ntambi J.

Since last promotion to Professor (in Sept 2018)

5. Zheng J, Chen T, Guo X, Ntambi J, and **Wu C (corresponding author)**. Interplays between nutritional and inflammatory signaling and fat metabolism in pathophysiology of NAFLD. (2020) Chapter 14, in Lipid Signaling and Metabolism, Editor: Ntambi J.
6. Li H, Guo X, Aquino E, and **Wu C (corresponding author)**. Uncoupling of Fat Deposition and Inflammation during Non-alcoholic Fatty Liver Disease (2023) Chapter, in Cellular Lipid in Health and Disease, Editor: Ntambi J.

Editor-Reviewed Publications

1. **Wu C.**, Khan S.A., and Lange A.J. (*Invited review*) Regulation of glycolysis – Role of insulin. *Exp Gerontol*, 2005, 40: 894–899.
2. **Wu C.**, Okar D.A., and Lange A.J. (*Invited review*) Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. *Curr Drug Targets-IEMD*, 2005, 5:51-59.

Since faculty appointment as Assistant Professor (in Sept 2007)

3. Okar D.A., Lange A.J., and **Wu C.** Interaction with PFK-2/FBP-2 is essential to glucokinase molecular physiology. *Cell Mol Life Sci* 2009, 66: 731-732.
4. Guo X. (**PhD student**), Li H., Xu H. (**PhD student**), Woo S.L. (**MS student**), Dong H., Lu F., Lange AJ, and **Wu C (corresponding author)**. (*Invited review*) Glycolysis in the control of blood glucose homeostasis. *Acta Pharmaceutica Sinica B*, 2012, 2(4):358–367.

Since promotion to Associate Professor (in Sept 2013)

5. Woo SL (**PhD student**), and **Wu C** (*corresponding author*). (2014) Research Highlight: Metformin improves aspects of obesity-associated NAFLD. *Immunoendocrinology* 2014; 1: e280. doi: 10.14800/Immunoendocrinology
6. Zheng J, Woo SL, Hu X, Botchlett R, Chen L, Huo Y, and **Wu C** (*corresponding author*). (2015) Metformin and metabolic diseases: a focus on hepatic aspects. *Front Med*, 2015;9:173-86. doi: 10.1007/s11684-015-0384-0. PMID: 25676019.
7. Mashek DG, **Wu C** (*corresponding author*). (2015) MUFAs *Adv Nutr* 2015 May 15;6(3):276-7. doi: 10.3945/an.114.005926.
8. Yu J, Marsh S, Hu J, Feng W, and **Wu C**. (2016) The pathogenesis of non-alcoholic fatty liver disease: Interplay between diet, gut microbiota, and genetic background *Gastroenterol Res Pract*. 2016;2016:2862173. doi: 10.1155/2016/2862173. Epub 2016 May 9. Review.
9. Yu J, Marsh S, Hu J, Feng W, and **Wu C**. (2016) Gut microbiota and metagenomic advancement in digestive disease. *Gastroenterol Res Pract*. 2016;2016:4703406. doi: 10.1155/2016/4703406. Epub 2016 May 10.
10. Botchlett R (**PhD student**), Woo SL (**PhD student**), Liu M (**Postdoc**), Pei Y (**PhD student**), Guo X (**Postdoc**), Li H, **Wu C** (*corresponding author*). Nutritional approaches for managing obesity-associated metabolic diseases. *J Endocrinol*, 2017 Jun;233(3):R145-R171. doi: 10.1530/JOE-16-0580.

Since last promotion to Professor (in Sept 2018)

11. Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. (2020) Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. *Front Med* (Lausanne). 2020 Jul 29;7:361. doi: 10.3389/fmed.2020.00361. eCollection 2020.
12. Wu N, Baiocchi L, Zhou T, Kennedy L, Ceci L, Meng F, Sato K, Wu C, Ekser B, Kyritsi K, Kundu D, Chen L, Meadows V, Franchitto A, Alvaro D, Onori P, Gaudio E, Lenci I, Francis H, Glaser S, Alpini G. (2020) Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury. *Hepatology*. 2020 Dec;72(6):2219-2227. doi: 10.1002/hep.31484. Epub 2020 Nov 19. PMID: 32737904
13. Zhang J, Zhu S, Ma N, Johnston LJ, **Wu C**, Ma X. (2020) Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation. *Med Res Rev* 2021 Mar;41(2):1061-1088. doi: 10.1002/med.21752. Epub 2020 Nov 10. PMID: 33174230
14. Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, **Wu C**, Chakraborty S, Glaser S, Alpini G. (2020) Cholangiocarcinoma: Bridging the translational gap from preclinical to clinical development and implications for future therapy. *Expert Opin Investig Drugs* 2021 Apr;30(4):365-375. doi: 10.1080/13543784.2021.1854725. Epub 2020 Dec 8. PMID: 33226854
15. Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. (2021) Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. *Obes Rev* 2021 Nov;22(11):e13316. doi: 10.1111/obr.13316. Epub 2021 Jul 18. PMID: 34279051

16. Zhou M, Johnston LJ, **Wu C**, Ma X. (2021) Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases. *Crit Rev Food Sci Nutr*. 2021 Oct 26;1-18. doi: 10.1080/10408398.2021.1986466. Online ahead of print. PMID: 34698581
17. Zhang W, Guo X, Chen L, Chen T, Yu J, **Wu C**, Zheng J. Ketogenic Diets and Cardio-Metabolic Diseases. *Front Endocrinol* (Lausanne). 2021 Nov 2;12:753039. doi: 10.3389/fendo.2021.753039. eCollection 2021. PMID: 34795641
18. Wang X, Rao H, Liu F, Wei L, Li H, **Wu C (corresponding author)**. Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. *Cells*. 2021 Nov 25;10(12):3300. doi: 10.3390/cells10123300. PMID: 34943809 Invited review
19. Wan Y, Li X, Slevin E, Harrison K, Li T, Zhang Y, Klaunig JE, **Wu C**, Shetty AK, Dong XC, Meng F. Endothelial dysfunction in pathological processes of chronic liver disease during aging. *FASEB J*. 2022 Jan;36(1):e22125. doi: 10.1096/fj.202101426R. PMID: 34958687
20. Meadows V, Baiocchi L, Kundu D, Sato K, Fuentes Y, **Wu C**, Chakraborty S, Glaser S, Alpini G, Kennedy L, Francis H. (2022) Biliary Epithelial Senescence in Liver Disease: There Will Be SASP. *Front Mol Biosci* 2021 Dec 21;8:803098. doi: 10.3389/fmolb.2021.803098. eCollection 2021. PMID: 34993234
21. Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, Ekser B, Milana M, Zhang W, **Wu C**, Sato K, Chakraborty S, Glaser SS, Francis H, Alpini G, Baiocchi L. Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. *Cancers* (Basel). 2022 Mar 11;14(6):1442. doi: 10.3390/cancers14061442. PMID: 35326593
22. Slevin E, Koyama S, Harrison K, Wan Y, Klaunig JE, **Wu C**, Shetty AK, Meng F. (2023) Dysbiosis in gastrointestinal pathophysiology: Role of the gut microbiome in Gulf War Illness. *J Cell Mol Med*. 2023 Jan 30. doi: 10.1111/jcmm.17631. Online ahead of print. PMID: 36716094
23. Li H, Guo X, Aquino E, and **Wu C (corresponding author)**. (2023) Mini review: STING activation during non-alcoholic fatty liver disease. *Front Nutr*. 2023 Mar 1;10:1139339. doi: 10.3389/fnut.2023.1139339. eCollection 2023. PMID: 36937350
24. Yu J, Zheng J, **Wu C (corresponding author)**. An essential role for hepatocyte adenosine kinase in regulating fat metabolism and inflammation. 2024 Cell Signal (Middlet). 2024;2(1):58-60. doi: 10.46439/signaling.2.029.

V. TEACHING

Cumulative Summary of Students/Trainees Supervised

Graduate Student Committee Involvement

Degree	Since Last Promotion (Sept 2018)		Career	
	Chair or Co-chair	Member	Chair or Co-chair	Member
Master of Science	4	9	9	19

Curriculum Vitae: Chaodong Wu, MD, PhD

PhD	2	22	7	32
-----	---	----	---	----

Undergraduate Students, Visiting Graduate Students and Postdocs Supervised

	Since Last Promotion (Sept 2018)	Career
Degree	Supervisor	Supervisor
Undergraduate Students	12	34
Visiting PhD Students	2	6
Postdoctoral Associate	2	8

A. Courses Taught (since appointment at TAMU, * guest lecture)

NUTR 475 (or NUTR 470, NFSC 475), Nutrition and Physiological Chemistry

NUTR 481 (or NFSC 481), Nutrition Seminar

FSTC 489*, Special Topics in Probiotics & Microbiology

FSTC 489*, Special Topics in Religious and Ethnic Foods
(Renamed as NUTR/FSTC 415, NUTR/FSTC 315, and then NUTR 300)

NUTR 485/491 (or NFSC 485/491), Directed undergraduate Research of Nutrition

BIOL 613*, Cell Biology

NUTR 630* (now NFSC 630), Nutrition in Disease

NUTR 642 (or NFSC 642), Nutritional Biochemistry

NUTR 681 (or NFSC 681), Nutrition Seminar

NUTR 685 (or NFSC 685), Directed Nutrition Graduate Research

NUTR 685, High Impact Learning - Nutrition Obesity Seminar Series

NUTR 689, Advanced Nutrition, Module 2

NUTR 691 (or NFSC 691), Graduate Research of Nutrition

B. Seminars and Guest Lectures

TAMU seminars and guest lectures

1. 10/02/2007: PFKFB Genes and Metabolic Diseases, Invited talk

Curriculum Vitae: Chaodong Wu, MD, PhD

- The Intercollegiate Faculty of Nutrition, Texas A&M University,
College Station, TX.
2. 03/26/2008: Role of Liver in Metabolic Regulation – Perspectives of Nutrition and Physiology, Guest lecture,
FSTC 489 (Special Topics in Probiotics & Microbiology) students
 3. 03/19/2009: Chinese Food and Culture, Guest lecture,
FSTC 489 (Special Topics in Religious and Ethnic Food) students
 4. 03/29/2010: Chinese Food and Culture, Guest lecture
FSTC 489 (Special Topics in Religious and Ethnic Food) students
 5. 09/06/2010: Novel Aspects of Overnutrition-associated Adipose Tissue
Inflammatory Response and Systemic Insulin Resistance, Invited talk
The Intercollegiate Faculty of Nutrition, Texas A&M University,
College Station, TX.
 6. 11/1/2010: Chinese Food and Culture, Guest lecture
FSTC 489 (Special Topics in Religious and Ethnic Food) students
 7. 02/22/2011: Regulation of Adipose Tissue Inflammatory Response and Systemic
Insulin Resistance Independent of Adiposity, Invited talk
Department of Biology, Texas A&M University, College Station, TX.
 8. 03/17/2011: Role of Adipose Tissue in Fatty Liver Disease: Adiposity versus
Inflammation, Invited talk, the Institute of Bioscience and Technology,
Texas A&M Health Science Center, Houston, TX.
 9. 04/14/2011: Cell Signaling: Perspectives in Nutritional Physiology, Guest lecture,
BIOL 613 (Cell Biology) students, Department of Biology, Texas A&M
University, College Station, TX.
 10. 11/02/2011: Chinese Food and Culture, Guest lecture
NUTR 415 (Special Topics in Religious and Ethnic Food) students
 11. 12/08/2011: Metabolic Regulation of Adipose Tissue Inflammatory Response in
Obesity, Invited talk
Cardiovascular Research Institute, Texas A&M University Health
Science Center, College Station, TX.
 12. 04/12/2012: Cell Signaling: Perspectives in Nutritional Physiology, Guest lecture,
BIOL 613 (Cell Biology) students, Department of Biology, Texas A&M
University, College Station, TX.
 13. 10/10/2012: Lipid and Health: Hepatic Events of Palmitoleate Supplementation,
Guest lecture, NUTR 289 (Current Perspectives in Nutrition) students
 14. 10/31/2012: Chinese Food and Culture, Guest lecture
NUTR 300 (Religious and Ethnic Foods) students
 15. 12/07/2012: Metabolic Regulation of Adipocyte-macrophage Crosstalk in Obesity,
Seminar talk,
The Center for Biological Clocks Research at Texas A&M
 16. 05/10/2013: Circadian Clocks Regulation of Macrophage Activation and Insulin
Resistance in Obesity. Seminar talk,
The Center for Biological Clocks Research at Texas A&M

Since promotion to Associate Professor (in Sept 2013)

Curriculum Vitae: Chaodong Wu, MD, PhD

17. 09/09/2013: Health Obesity: PFKFB3 Uncoupling Fat Deposition and Inflammation, Invited talk, Toxicology seminar series, Texas A&M University, College Station, TX.
18. 10/28/2013: Chinese Food and Culture, Guest lecture
NUTR 300 (Religious and Ethnic Foods) students
19. 05/09/2014: Myeloid Cell-specific Circadian Clock Dysregulation Exacerbates Insulin Resistance during obesity, Seminar talk,
The Center for Biological Clocks Research at Texas A&M
20. 05/15/2014: Grand Challenge: Obesity and Metabolic Diseases
Invited talk,
COALS Grand Challenge Mini-Symposia, Texas A&M
21. 10/31/2014: Texas A&M Nutrition Obesity Research mini-symposium
Invited talk,
College Station, Texas A&M University
22. 11/06/2014: Circadian Dysregulation and Inflammation during Obesity
Invited talk,
Human Health and Kinesiology seminar series, Texas A&M University,
College Station, TX.
23. 11/17/2014: Chinese Food and Culture, Guest lecture
NUTR 300 (Religious and Ethnic Foods) students
24. 09/05/2016: Inflammation in obesity-related diseases: a focus on fat tissue
Guest lecture for NUTR 630 (Nutrition in Disease)
25. 05/05/2017: Novel Role for Cyclic GMP-AMP in Link Inflammation and Metabolism
Seminar talk,
The Center for Biological Clocks Research at Texas A&M

Since last promotion to Professor (in Sept 2018)

26. 04/02/2019: STING Links Innate Immunity, Insulin Resistance, and NAFLD
Invited talk,
VTPP, Texas A&M
27. 12/05/2019: Pathophysiology of Obesity-associated Insulin Resistance and NAFLD:
Role of Adenosine 2A Receptor
Invited talk,
MCM, Texas A&M College of Medicine
28. 01/29/2021: Uncoupling Fat Deposition and Inflammation: Cell-type-specific Roles
for PFKFB3 in Metabolic Diseases
Invited lecture for NUTR 681 (Nutrition seminar)
29. 04/08/2021: Interplays between Inflammation and Metabolism in Obesity: Path to A
Molecular Nutritionist
Invited lecture for Nutrition Science Graduate Association, TAMU
30. 03/09/2022: Role of microbiota metabolite indole in pathophysiology of NAFLD
Invited talk,
Medical Physiology, Texas A&M College of Medicine
31. 03/31/2023: Hepatocyte Control of Fat Deposition and Liver inflammation

Monthly seminar, Texas A&M University Center for Biological Clocks
Research, College Station, TX

Other universities (state, national, and international)

1. 02/04/2009: PFKFB Genes and Metabolic Diseases, Invited talk
UT Southwestern Medical Center at Dallas, Dallas, TX, the obesity
outreach program
2. 10/17/2010: Regulation of Overnutrition-associated Adipose Tissue Inflammatory
Response and Systemic Insulin Resistance: Novel Concepts, Invited talk
for 110th Anniversary of Tongji Hospital
Tongji Hospital, Tongji Medical College of Huazhong University of
Science and Technology, Wuhan, China
3. 10/23/2010: A Novel Role for Adipose Tissue in NAFLD/NASH, Invited talk
The Institute of Hepatology, Peking University Health Science Center,
Beijing, China
4. 04/20/2012: Metabolic and Inflammatory Aspects of Palmitoleate Supplementation:
Good and Bad, Invited talk
University of Illinois at Urbana Champaign, Champaign, Illinois,
5. 07/17/2012: Metabolic Regulation of Obesity-associated Risk in Relation to
Atherosclerosis, Invited talk
The Third Hospital of Sun Yat-sen University, Guangzhou, China
6. 07/18/2012: Healthy Obesity: Dissociation of Fat Deposition and Inflammatory
Responses in Adipose and Liver tissues, Invited talk
Union Hospital, Tongji Medical College of Huazhong University of
Science and Technology, Wuhan, China

Since promotion to Associate Professor (in Sept 2013)

7. 11/08/2013: Uncoupling Fat Deposition and Inflammation in Obesity
Invited talk
University of North Dakota, Grand Forks, North Dakota
8. 07/05/2014: Circadian Clock Dysregulation and Diabetes
Invited talk
The 6th Union Hospital Endocrinology Forum, Wuhan, China
9. 07/05/2014: PFKFB3 Control of Tongue Cancer by Responding to Circadian Clock
Outputs, Invited talk
Union Hospital, Tongji Medical College, Wuhan, China
10. 07/07/2014: It's all in the timing: Circadian Clocks, Macrophage Activation, and
Insulin Resistance, Invited talk
Peking University Shenzhen Graduate School, Shenzhen, China
11. 07/08/2014: Circadian Clock Regulation of Macrophage Activation and Insulin
Sensitivity in Obesity, Invited talk
The Third Hospital of Sun Yat-sen University, Guangzhou, China
12. 07/09/2014: NAFLD Pathophysiology and Intervention: New Aspects
Invited talk

Curriculum Vitae: Chaodong Wu, MD, PhD

- Hubei Hospital of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China
13. 07/14/2014: Circadian Clock Dysregulation Underlies Inflammation and Insulin Resistance in Obesity, Invited talk
Tongji Hospital of Tongji Medical College, Wuhan, China
 14. 11/10/2014: Uncoupling Fat Deposition and Inflammation in Obesity
Invited talk
Virginia Tech, Blacksburg, VA
 15. 04/01/2015: Regulation of Macrophage Activation and Insulin Resistance in Obesity
Invited talk
University of Minnesota, Minneapolis, MN
 16. 08/11/2015: Obesity-associated NAFLD: Pathophysiology and Intervention
Invited talk
Chongqing Medical University, Chongqing, China
 17. 10/08/2015: Regulation of Macrophage Activation and Insulin Sensitivity in Obesity
Invited talk
The Children's Nutrition Research Center, Houston, Texas
 18. 10/28/2015: Role for Inflammation in Pathophysiology and Intervention of NAFLD
Invited talk
Hubei Hospital of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China
 19. 10/29/2015: Metformin Intervention of Obesity-associated NAFLD
Invited talk
The First International Biomedical Forum of Tongji Hospital, Tongji Hospital of Tongji Medical College, Wuhan, China
 20. 10/30/2015: Obesity and Metabolic Diseases: Challenges and Opportunities
Invited talk
Wuhan Polytechnic University, Wuhan, Hubei, China
 21. 11/06/2015: Regulation of Macrophage Activation and Insulin Sensitivity in Obesity
Invited talk
The Institute of Molecular Medicine, UT Health Science Center at Houston, Houston, Texas
 22. 12/10/2015: Obesity and Metabolic Diseases: Wu Lab Research
Invited talk
Soochow University, Suzhou, Jiangsu, China
 23. 12/15/2015: Regulation of Fat Deposition and Inflammation In Obesity-associated NAFLD
Invited talk
Shanghai University/the Second Military Medical University, Shanghai, China
 24. 01/22/2016: Regulation of Macrophage Activation in Obesity: Roles for Metabolism and Timing
Invited talk
University of New Mexico, New Mexico
 25. 02/11/2016: Metabolic and Circadian Control of Macrophage Activation in Obesity
Invited talk

Curriculum Vitae: Chaodong Wu, MD, PhD

- Georgia State University, Atlanta, Georgia
26. 04/19/2016: Metabolic and Circadian Control of Macrophage Activation in Obesity
Invited talk (cancelled due to bad weather)
Texas Tech University, Lubbock, Texas
 27. 04/28/2016: Regulation of Adipose Tissue Inflammation in Obesity: Roles of Metabolism and Circadian Clock
Invited talk
Dalian Medical University, Dalian, China
 28. 01/04/2017: Metabolic Regulation of Obesity-associated Risk in Relation to CVD
Invited talk
Augusta University, Augusta, Georgia,
 29. 03/30/2017: Pathophysiology of Fat Deposition and Inflammation in Obesity-associated NAFLD
Invited talk
Wayne State University, Detroit, Michigan
 30. 05/25/2017: Metformin Treatment of Obesity-associated NAFLD: New Insights
Invited talk
Baylor Scott & White Health, Digestive Disease Research Center & Department of Gastroenterology, Temple, Texas
 31. 09/27/2017: Pathophysiological Role of Inflammation in Obesity-associated NAFLD
Invited talk, Peking University Health Science Center, Beijing, China

Since last promotion to Professor (in Sept 2018)

32. 11/02/2018: Uncoupling Fat Deposition and Inflammation in Obesity-associated NAFLD
Invited talk, Sun Yat-sen University, Guangzhou, China
33. 11/05/2018: Obesity and Metabolic Diseases
Invited talk, Shandong University, Jinan, Shandong, China
34. 11/06/2018: Role of Innate Immunity in Insulin Resistance and NAFLD
Invited talk, Tongji Medical College, Wuhan, Hubei, China
35. 12/27/2018: Role of Innate Immunity in Insulin Resistance and NAFLD
Invited talk, Central South University, Changsha, Hunan, China
36. 12/28/2018: STING Links Innate Immunity, Insulin Resistance, and NAFLD
Invited talk, Wuhan University, Wuhan, Hubei, China
37. 03/20/2019: Role of Role of STING in Insulin Resistance and Non-alcoholic Fatty Liver Disease
Invited talk, Wayne State University, Detroit, Michigan
38. 08/15/2019: Role of Inflammation in Insulin Resistance and NAFLD
Invited talk, China Agriculture University, Beijing, China
39. 11/01/2019: Inflammation and Pathophysiology of NAFLD
Invited talk, Sun Yat-sen University, Guangzhou, China
40. 04/27/2019: Role of Inflammation in Pathophysiology of NAFLD
Invited talk, University of Kansas, Kansas
41. 12/19/2021: Interplays between Inflammation and Metabolism in Obesity: A Path to Molecular Nutritionist

Curriculum Vitae: Chaodong Wu, MD, PhD

- Invited talk, Huazhong University of Science and Technology
Invited lecture for Dental School Distinguished Lecture Series
42. 09/22/2022: Hepatocyte Control of Fat Deposition and Liver Inflammation
Invited talk, Indiana University Liver Research Center Symposium
Indianapolis, IN
 43. 12/29/2022: Hepatocyte Control of Fat Deposition and Liver Inflammation
Guangdong University of Chinese Medicine, Virtual
 44. 03/30/2023: Regulation and Pathophysiological Role of STING in Liver Diseases
Cancer Center Work in Progress Meeting
Houston Methodist Hospital, TX, Virtual
Houston Methodist Hospital, TX, Virtual
 45. 04/27/2023: Regulation and Pathological Role of STING in Liver Diseases
University of Nebraska, Lincoln
Lincoln, Nebraska
 46. 08/30/2023: Interplays of Metabolism and Inflammation in Obesity and Metabolic
Diseases
University of Missouri, Columbia, MO

Professional Societies

1. 06/05/2009: Role of PFKFB3 in the Control of Adipose tissue Inflammation and
Systemic Metabolism
Invited talk, *Chinese American Diabetes Association*, New Orleans, LA
2. 04/27/2010: Involvement of PFKFB3/iPKF2 in the Suppressive Effect of
Rosiglitazone on Diet-induced Intestine Inflammatory Response
Oral presentation, *Experimental Biology*, Anaheim, CA
3. 04/12/2011: Adipocyte PFKFB3 Overexpression Protects Mice from Diet-Induced
Adipose Tissue Inflammation and Systemic Insulin Resistance
Oral presentation, *Experimental Biology*, Washington DC
4. 04/12/2011: A Novel Mechanism for the Insulin-Sensitizing Effect of Leucine in
Adipocytes
Oral presentation, *Experimental Biology*, Washington DC
5. 06/23/2011: A Critical Role for Adipose Tissue in Regulating Diet-induced Liver
Inflammatory Response
Oral presentation, *Chinese American Diabetes Association*, San Diego,
CA
6. 04/21/2012: Palmitoleate Supplementation Dissociates Liver Inflammatory Response
from Hepatic Steatosis in Mice
Oral presentation, *Experimental Biology*, San Diego, CA
7. 03/23/2013: Is Circadian Clock Dysregulation Linked to Adipose Tissue
Inflammation in Obesity?
Oral presentation, *the Southeastern and Central Texas Society for
Clocks*, College Station, TX
8. 06/24/2013: Adenosine 2A receptor protects against diet-induced hepatic steatosis
and insulin resistance in mice
Oral presentation, *Chinese American Diabetes Association*, Chicago, IL

Since promotion to Associate Professor (in Sept 2013)

9. 04/28/2014: Advancing nutrition knowledge on metabolic diseases through collaborative research between the US and China, International Forum – China
Invited talk, *Experimental Biology*, San Diego, CA
10. 05/18/2015: Timing Matters: Circadian Clock Control of Inflammation and Insulin Resistance in Obesity
Invited talk, *the 12th Congress of Chinese Nutrition Society*, Beijing, China
11. 06/28/2015: Circadian Clock Dysregulation Links Inflammation and Insulin Resistance in Obesity
Invited talk, *the 15th Society of Chinese Bioscientists in America (SCBA) International Symposium*, Taipei, ROC
12. 10/09/2015: Pathophysiology of fat deposition and inflammation in obesity-associated NAFLD
Invited talk, *the Kutscher Digestive Disease Research Center Symposium*, Temple, Texas
13. 11/26/2015: Berberine Improves Glucose Homeostasis and Aspects of NAFLD by Suppressing Inflammation
Invited talk, *the 5th Annual World Congress of Endocrinology-2015 & the 4th Annual World Congress of Diabetes-2015*, Kaohsiung, Taiwan, ROC
14. 12/11/2015: Intestine Inflammation during Obesity: Metabolic Regulation and Actions of PPAR γ Activation
Invited talk, Dr. Wu was selected as one of 5 Chinese American scientists to represent the Chinese American Diabetes Association *The 19th Scientific Meeting of the Chinese Diabetes Society*, Suzhou, Jiangsu, China
15. 03/23/2016: Inflammation in Obesity-associated Metabolic Diseases: Regulation and Pathophysiological Roles
Invited talk, *the North America Chinese Society for Nutrition (NACSN) 's Webinar series*, Hosted by NACSN via East Tennessee State University, Johnson City, TN
16. 04/02/2016: PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs
Invited talk, Annual Meeting of *Texas Society for Clocks in Biology and Medicine*, College Station, TX
17. 04/26/2016: A Role for PFKFB3 in Nutritional Control of Intestinal inflammation
Invited talk, *the 6th Annual World Congress of Molecular & Cell Biology 2016*, Dalian, China
18. 06/17/2016: A New Dinucleotide Protects Against Obesity-Associated Fatty Liver Disease
Invited talk, *the 14th Annual Congress of International Drug Discovery Science & Technology – South Korea 2016*, Gyeonggi, South Korea
19. 05/19/2017: Cyclic GMP-AMP Ameliorates Diet-induced Metabolic Dysregulation

Curriculum Vitae: Chaodong Wu, MD, PhD

- and Regulates Proinflammatory Responses Distinctly from STING Activation
Invited talk, *the First South Texas Nutrition Obesity Symposium 2017*, College Station, Texas
20. 06/17/2017: Cyclic GAMP as A Mediator Linking Inflammation and Metabolism
Invited talk, *the Fifth West China "Two-River" Endocrinology Forum*, Chongqing, China
21. 07/13/2017: Cyclic GMP-AMP Improves Diet-induced Insulin Resistance by Ameliorating Inflammation
Invited talk, *the 5th World Congress of Diabetes 2017*, Prague, Czech Republic
22. 07/27/2017: Involvement of AMPK in the beneficial effects of metformin
Invited talk, *the 15th Annual Congress of International Drug Discovery Science & Technology - Japan 2017*, Osaka, Japan
23. 09/23/2017: Regulation of Fat Deposition and Inflammation in Obesity-associated NAFLD
Invited talk, *The Sixth Endocrinology and Metabolic Disease Forum in Wuhan*, Wuhan, China
24. 09/24/2017: Role of Cyclic GAMP in linking Inflammation and Metabolism
Invited talk, *The 14th Guangdong Cardiology Annual Meeting*, Guangzhou, China
25. 10/09/2017: Role of Adenosine 2A Receptor in Pathophysiology of Non-alcoholic Fatty Liver Disease
Invited talk, *the Kutscher Digestive Disease Research Center Symposium*, Temple, Texas

Since last promotion to Professor (in Sept 2018)

26. 09/23/2018: Circadian Dysregulation Links Nutrition Stress and Insulin Resistance
Invited talk, *the First International Conference on Precision Nutrition and Metabolism in Public Health and Medicine*, Chania, Crete, Greece
27. 10/10/2018: Role of Innate Immunity in Obesity and Insulin Resistance
Invited talk, *Nutrition Obesity Workgroup Symposium in Houston*, TX
28. 11/03/2018: Role of Innate Immunity in Insulin Resistance and Metabolic Diseases
Invited talk, *The 15th Guangdong Cardiology Annual Meeting*, Guangzhou, China
29. 11/03/2018: Circadian Clock Dysregulation Links Nutrition Stress and Insulin Resistance
Invited talk, *The 2018 Chinese Diabetes Society Diabetes and Obesity Annual Meeting*, Guangzhou, China
30. 11/29/2018: Adenosine 2A Receptor Links Innate Immunity and Systemic Insulin Sensitivity
Invited talk, *The 22nd Scientific Meeting of the Chinese Diabetes Society*, Suzhou, Jiangsu, China

Curriculum Vitae: Chaodong Wu, MD, PhD

31. 12/16/2018: Adenosine 2A Receptor Links Innate Immunity, Metabolism, and Insulin Sensitivity
Invited talk, The 2018 Texas Immunometabolism Symposium, College Station, Texas
32. 05/11/2019: Inflammation and Pathophysiology of NAFLD
Invited talk, The 7th Western China Diabetes Forum and the First International Endocrine Hypertension Forum, Chongqing, China
33. 08/18/2019: Inflammation and Pathophysiology of NAFLD
Invited talk, International Symposium on Cancer Metabolism & Precision Cancer Therapy, Chinese Society of Cancer Metabolism, Chinese Anti-Cancer Association, Chongqing, China
34. 11/02/2019: Role of Inflammation in Insulin Resistance and Metabolic Diseases
The 2nd International Forum of Diabetes and Obesity in Guangzhou, Guangzhou, China
35. 04/23/2020: Role of Innate Immunity in Metabolic Diseases
Seminar Series of the Chinese American Diabetes Association, Virtual
36. 06/18/2020: Role of STING in NAFLD and Insulin Resistance
the JMCB Symposium on Biomedical Frontier 2020, Hangzhou, China
Cancelled due to COVID-19
37. 10/18/2020: Role of Innate Immunity in NAFLD and HCC
Seminar series, China Society for Cancer and Metabolism, Virtual
38. 10/30/2020: Differential Roles for PFKFB3 in Regulating Hepatic Steatosis and Inflammation in Cell Type-dependent Manners
The 3rd Chinese Americans for Liver Society Annual Symposium, Virtual
39. 11/28/2020: Diets and Cardiovascular Diseases
The 2020 Annual Scientific Meeting of the Society of Guangdong Chinese and Western Medicines, Virtual
40. 09/25/2021: Role of Microbiota Metabolite Indole in Obesity and Metabolic Diseases
The 2021 International Scientific Meeting of Food Safety, Nutrition, and Human Health, Beijing/Wuhan, Virtual
41. 10/29/2021: Intestinal inflammation is increased in MCD diet-induced NASH
The 4th Chinese Americans for Liver Society Annual Symposium, Virtual
42. 12/05/2021: Metformin and Risk of Atherosclerosis
The 2021 Annual Scientific Meeting of the Society of Guangdong Chinese and Western Medicines, Virtual
43. 03/03/2022: Role of Inflammation in the Pathophysiology of NAFLD
Seminar series for Chinese Americans for Liver Society, Virtual
44. 07/30/2022: Role of microbiota metabolite indole in NAFLD/NASH
The 18th SCBA Biennial Meeting Program, Boston, July 27-31, 2022
45. 07/25/2023: Hepatocyte adenosine kinase promotes steatotic liver disease
The 3rd Edition of webinar on Gastroenterology & Hepatology (Online EVENT), July 24-25, 2023
46. 08/09/2023: Regulation and Pathological Role of STING in SLD

Curriculum Vitae: Chaodong Wu, MD, PhD

- Chinese American Liver Society, Summer Symposium, Banff Moose Hotel & Suites, Canada, August 6-10, 2023
47. 09/22/2023: Hepatocyte ADK Promotes Steatotic Liver Disease and Increases Angiogenesis
The 12th World Congress of Microcirculation, Beijing, China, via Zoom.
 48. 12/24/2023: Regulation and Pathological Role of STING in MASLD
2023's Guangdong Society for Pathophysiology/Guangdong University of Chinese Medicine, Virtual
 49. 06/13/2024: Regulation and Pathological Role of STING in MASLD
2024's CADA Scientific Meeting at Orlando, FL
 50. 07/28/2024: Interplays between Inflammation and Metabolism in MASLD
2024's International Conference on Life Sciences and the 19th SCBA Biennial Symposium, Guiyang, China

VI. SERVICE

A. Leadership Role (Organizer/Organizing Committee; Chair/Co-Chair/Director)

Organizer/Organizing Committee

1. 09/01/2014 - 10/31/2014
Chair of the organizing committee for the First Texas A&M Nutrition Obesity Symposium, College Station, TX
2. 11/13/2015 – 04/04/2016
Chair of the organizing committee for the Scientific Meeting of the North America Chinese Society for Nutrition, San Diego, CA
3. 01/04/2016 – 04/08/2016
Organizer of the Second Texas A&M Nutrition Obesity Symposium
College Station, TX
4. 01/06/2016 - 12/2016
Organizing committee member, the 10 International Conference and Exhibition on for Obesity & Weight Management, Dec 08-10, Dallas, TX
5. 02/06/2017 – 05/19/2017
Organizer of the 2017 South Texas Nutrition Obesity Symposium (TAMU-TMC Joint Obesity Forum), College Station, TX
6. 03/01/2017 – 09/27/2017
Organizing committee member, the Belt and Road Initiative Global Health International Congress & 2017 Chinese Preventive Medicine Association - Chinese Society on Global Health Annual Meeting, September 24 - 27, 2017, Xi'an, China
Session Chair, Dialogue with Editors; Session Co-Chair, Nutrition Forum

Curriculum Vitae: Chaodong Wu, MD, PhD

7. 05/12/2017 – 07/28/2017
Organizing committee member, the 13 International Congress on Advances in Natural Medicines, Nutraceuticals & Neurocognition July 27-28, 2017 Rome, Italy
8. 05/12/2017 – 11/14/2017
Organizing committee member, World Summit on Obesity and Weight Management, Nov 13-14, 2017, Chicago, IL
9. 05/19/2017 – 10/05/2017
Organizing committee member, the Joseph E. and Martha E. Kutscher Digestive Disease Research Center (DDRC) Symposium. Oct 4-6, 2017, Temple, TX
10. 01/05/2018 – 04/27/2018
Organizer, 2018 Texas A&M Nutrition Obesity Research Symposium, April 27, 2018, Temple, TX
11. 12/20/2019 – 05/15/2020
Organizing committee member, Texas A&M University TICER Research Symposium
May 15, 2020, College Station, TX
12. 08/01/2020 – 07/31/2021
Organizer for Fontiers in Nutrition Seminar Series, Director of Scientific Advisory Committee, North American Chinese Association for Nutrition.
13. 05/01/2021 – 07/17/2021
Organizer, Joint Scientific Symposium of North American Chinese Association for Nutrition and International Chinese Nutrition Young Scholar Network

Other Organizer/Organizing Committee (invited, but rejected due to busy schedule)

1. 02/17/2017: Organizing committee member, International Conference on Obesity and Weight Loss, November-6-8, 2017 at Rome, Italy.
2. 03/08/2017: The International Conference on Obesity Medicine (Obesity Medicine 2017), October 30- November 01 2017 at Bangkok, Thailand
3. 04/28/2017: The 19th International Congress on Nutrition & Health” April 13-15, 2018 Amsterdam

Chair/Co-Chair/Director

1. 04/12/2011: Co-Chair of the Nutrient-Gene Interaction mini-symposium of the American Society for Nutrition at Experimental Biology
Washington DC
2. 04/21/2012: Co-Chair of the Nutrient-Gene Interaction mini-symposium of the American Society for Nutrition at Experimental Biology

Curriculum Vitae: Chaodong Wu, MD, PhD

3. 07/01/2014- 06//01/2016
San Diego, CA
North America Chinese Society for Nutrition
Member of Leadership Team and Director of Scientific Program
4. 08/06/2014 - 03/18/2015
Selected by the Vice President for Research of TAMU to lead Texas Nutrition Obesity research team for a proposal of TAM Nutrition Obesity Research Center
5. 12/05/2014 - present
Selected by the College of Agriculture and Life Sciences to lead Texas Nutrition Obesity research team
6. 12/21/2014 - 03/30/2015
Chair of International Forum of China Interest Group of the American Society for Nutrition at Experimental Biology
Boston, MA
7. 06/28/2015: Co-Chair of a Metabolic Disease Mini-symposium of the 15th Society of Chinese Bioscientists in America (SCBA) International Symposium
Taipei, ROC
8. 11/13/2015 – 04/04/2016
Chair of International Forum of China Interest Group of the American Society for Nutrition at Experimental Biology
San Diego, CA
9. 11/27/2015: Chair of Session 2-1 at the 4th Annual World Congress of Diabetes
Kaohsiung, ROC
10. 04/27/2016: Chair of Forum 3-4: Diabetes, Obesity and Metabolic Syndrome at the 6th Annual World Congress of Molecular & Cell Biology 2016
Dalian, China
11. 06/17/2016: Chair of Section 6-4: Digestive System Diseases at the 14th Annual Congress of International Drug Discovery Science and Technology 2016
Seoul, South Korea
12. 07/13/2017: Chair of Track 14: Insulin Action & Secretion and Insulin Resistance at the 5th World Congress of Diabetes 2017, Prague, Czech Republic
13. 07/27/2017: Chair of Session 604: Metabolic Disorders (Part IV) - Other Metabolic Disorders at the 15th Annual Congress of International Drug Discovery Science and Technology 2017, Osaka, Japan
14. 07/27/2017: Session Chair: Dialogue with Editors of Top International Journals
The Belt and Road Initiative Global Health International Congress & 2017 Chinese Preventive Medicine Association - Chinese Society on Global Health Annual Meeting, September 26, 2017, Xi'an, China
15. 10/10/2018: Session Chair: Adipocytes in Metabolic Disorder
Texas Nutrition Obesity Workgroup Symposium
Houston, Texas
16. 12/16/2018: Session Chair: Inflammation and Metabolic Disease
Texas Immunometabolism Symposium
College Station, Texas
17. 10/31/2020: Session Co-Chair: Metabolic Liver Diseases

Curriculum Vitae: Chaodong Wu, MD, PhD

- The 3rd Chinese Americans for Liver Society Annual Symposium, Virtual
18. 07/16/2021: Chair, North America Chinese Association for Nutrition Scientific Summit, Virtual Symposium
19. 07/28/2024: Session Chair: Metabolic Dysfunction-associated Steatotic Liver Disease
2024's International Conference on Life Sciences and the 19th SCBA Biennial Symposium, Guiyang, China

B. Faculty Mentoring

Faculty Mentoring		
	Since Last Promotion (2018/09)	Career
	Mentor	Mentor
TAMU Tenure-track Assistant Professors	1	4
Non-TAMU Tenure-track Assistant Professors	1	3

C. Service to Department, College, and University

- 2007-present: Departmental Safety Committee, member, Chair (2008 -2009)
- 2007-2018: Departmental Facilities Committee, member, Chair (2014)
- 2009: Agricultural and Natural Resources Policy (ANRP) – screening committee
- 2009: Referee for poster section of the Intercollegiate Faculty of Nutrition Research Symposium
- 2010-2012: Member of graduate admission committee, Intercollegiate Faculty of Nutrition
- 2010-present: Departmental Award Committee, member, Co-Chair (2010-present), Chair (2012, 2013, 2018-present)
- 2011: Nutrition Interdisciplinary Degree Program (NUTR IDP) Transition Committee
- 2012: Departmental By-laws Committee
- 2012: Departmental Ad hoc Committee for Assessing Technical Knowledge
- 2012-present: Member of graduate admission committee, TAMU Nutrition graduate program
- 2013-present: Departmental Ad hoc Committee for Assessing Technical Knowledge
- 2013-2017: Graduate Program Committee of Nutrition and Food Science, elected
- 2013: Search committee for Head of Department of Nutrition and Food Science
- 2014-2015: Search committee for Assistant Professor of Department of Nutrition and Food Science
- 2016-2017: Graduate Student Selection Committee
- 2018-present: TAMU Research Development Fund Advisory Committee

Curriculum Vitae: Chaodong Wu, MD, PhD

- 2020: Chair, Instructional Assistant Professor Search Committee, Department of Nutrition
- 2020-present: Co-Chair, Tenure & Promotion Committee, Department of Nutrition
- 2020-2022: Member, Tenure & Promotion Committee, College of Agriculture and Life Sciences and AgriLife Research
- 2020-present: Member, Award Committee, College of Agriculture and Life Sciences and AgriLife Research

D. Service to National and International Societies, Organizations, and Governments

Professional Memberships and Activities

- 2001-present: Membership, American Diabetes Association
- 2002-2005: Full membership, Sigma Xi, The Scientific Research Society
- 2006: Senior editor, Medjaden Services Ltd.
- 2007-2012: Full membership, Intercollegiate Faculty of Nutrition
- 2009-present: Membership, Chinese American Diabetes Association
- 2009-present: Full membership, American Society of Nutrition
- 2012-present: ASN, committee members, Nutrient-Sensing Mechanisms
- 2012-present: ASN, committee members, Obesity
- 2014-2016: Member of Leadership Team and Co-Chair of Scientific Program of the North America Chinese Society for Nutrition
- 2016-present: Chair, Training and Communication Committee, International Chinese Nutrition Young Scholar Network (ICNYSN)
- 2017-2022: Vice President, ICNYSN
- 2018-present: Full membership, American Association for Study of Liver Disease (AALSD)
- 2020-2021: Director of Scientific Advisory Committee, North America Chinese Association for Nutrition (NACAN)
- 2021-2022: Vice President (President-Elect), North America Chinese Association for Nutrition (NACAN)
- 2022-present: President, North America Chinese Association for Nutrition (NACAN)

Grant Review

- 2009: External reviewer for Minnesota Agriculture Extension research proposals
- 2009: Ad hoc reviewer for Hepatobiliary Pathophysiology Study Section – HBPP, National Institutes of Health (NIH/NIDDK)
- 2010-2015: Member of peer-review committee (national), Vascular Wall Biology – Atherosclerosis study section, American Heart Association
- 2011-present: Member of peer-review committee, Life Science and Medical Science Sections, Chinese National Science Foundation
- 2012: Early Career Reviewer, Cellular Aspects of Diabetes and Obesity Study Section – CADO, National Institutes of Health (NIH/NIDDK)
- 2013: Ad hoc Reviewer, Integrative Physiology of Obesity and Diabetes Study Section – IPOD, National Institutes of Health (NIH/NIDDK)

Curriculum Vitae: Chaodong Wu, MD, PhD

- 2014: Ad hoc Reviewer, Heart, Lung, and Blood Program Project Review Committee – HLBPP/NIH
- 2014: Ad hoc Reviewer, Integrative Physiology of Obesity and Diabetes Study Section – IPOD, National Institutes of Health (NIH/NIDDK)
- 2015: Ad hoc Reviewer, Cellular Aspects of Diabetes and Obesity Study Section – CADO, National Institutes of Health (NIH/NIDDK)
- 2015: Ad hoc Reviewer, Integrative Physiology of Obesity and Diabetes Study Section – IPOD, National Institutes of Health (NIH/NIDDK)
- 2016: Ad hoc Reviewer, Cellular Aspects of Diabetes and Obesity Study Section – CADO, National Institutes of Health (NIH/NIDDK)
- 2016: Ad hoc Reviewer, Integrative Nutrition and Metabolic Processes Study Section – INMP, National Institutes of Health (NIH/NIDDK)
- 2016-present: Member of peer-review committee (national), Vascular Wall Biology – Atherosclerosis study section, American Heart Association
- 2016: Review panel, ZRG1 DKUS P-54 Special emphasis Panel, NIH
- 2017: Review Panel, Support of Competitive Research (SCORE) program, National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)
- 2017: Review Panel, Support of Competitive Research (SCORE) program, NIH/NIGMS
- 2017: Mail Reviewer, Diabetes Complications Consortium (DiaComp), NIDDK
- 2017: Ad hoc Reviewer, ZRG1 EMNR-W (02), NIH
- 2017: Ad hoc Reviewer, NIDDK DDK-B, NIH/NIDDK
- 2018: Review Panel, NNF, NIFA/USDA
- 2018: Ad hoc Reviewer, NIDDK DDK-B, NIH/NIDDK
- 2018: Ad hoc Reviewer, ACE, NIH
- 2018,2019: Ad hoc Reviewer, HCCS, NIH
- 2019-2023: Standing Member, HCCS, NIH
- 2021-2023: Chair, HCCS, NIH
- 2021,2022: External reviewer for University of Oklahoma Health Science Center (OUHSC) & Presbyterian Health Foundation (PHF), PHF Seed Grant Program
- 2021, 2022: External reviewer for Research Grant of Medical Research Council, United Kingdom
- 2022: External reviewer for the French National Research Agency (ANR) 2022
- 2023: ZDK1 GRB-C (O2), NIH
- 2023 Dec: ZRG1 KUDS Y-(03), SEP Panel, NIH (invited, but not be able to attend to conflict in schedule)
- 2024 Mar - Oct: NMHD/NIH; ZRG1 IIDB-X/NIH; ZDK1 GRB-C/NIH

Journal Review

- 2005-2008: Member of special editorial board, *Chinese J Gastroenterol Hepatol*
- 2009-present: Ad hoc reviewer for *Nutrition Research; Obesity*
- 2010-present: Ad hoc reviewer for *Experimental Biology and Medicine*

Curriculum Vitae: Chaodong Wu, MD, PhD

- 2005-2008: Member of special editorial board, *Chinese J Gastroenterol Hepatol*
- 2009-present: Ad hoc reviewer for *Nutrition Research; Obesity*
- 2010-present: Ad hoc reviewer for *Experimental Biology and Medicine*
- 2010-present: Member of editorial board, *Journal of Nutrition and Food Science*
- 2012-present: Ad hoc reviewer for *British Journal of Nutrition; PLoS ONE; International Journal of Biological Sciences; Molecular and Cellular Biochemistry; Journal of Molecular Endocrinology; International Journal of Obesity; and Journal of Lipid Research; PLoS Genetics; Hepatology; JCI Insights; Gut, Nature Communications, Adv Sci*
- 2016-present: Editorial board member, *Journal of Nutritional Biochemistry*
- 2019-present: Associate Editor-in-Chief, *Hepatology & Gastroenterology Letters*
- 2021-2022: Special Issue Editor, *Journal of Nutritional Biochemistry*
- 2021-2022: Special Issue Editor, *Frontiers in Endocrinology*

Tenure & Promotion Evaluation

- 2013: Huazhong University of Science and Technology
- 2014: University of Tennessee, Knoxville
- 2015: Brown University
- 2016: University of Connecticut
- 2016: University of North Florida
- 2016: The University of New Mexico, School of Medicine
- 2016: East Tennessee State University
- 2017: University of North Florida
- 2017: University of Nebraska - Lincoln
- 2018: Oklahoma State University
- 2019: Washington State University
- 2020: University of Tennessee, Knoxville
- 2020: University of Connecticut
- 2021: Queen's University Belfast, Belfast, United Kingdom
- 2021: University of Illinois Urbana-Champaign
- 2021: Baylor College of Medicine
- 2022: University of California, Los Angeles
- 2022: University of Macau
- 2022: Auburn University
- 2022: Iowa State University
- 2023: Georgia State University
- 2023: Temple University
- 2023: The University of New Mexico, School of Medicine
- 2024: Indiana University, School of Medicine
- 2024: Cleveland Clinic Foundation, Lerner Research Institute
- 2024: The University of New Mexico, School of Medicine
- 2024: University of North Florida

VII. PROFESSIONAL HONORS AND AWARDS

Curriculum Vitae: Chaodong Wu, MD, PhD

A. Awards

2001: Travel Award, the Center for Diabetes Research, University of Minnesota

2002&2005: Pilot & Feasibility Research Award, the Minnesota Obesity Center

2004: Travel Award, Dept. of BMBB, University of Minnesota

2004: Research Award, the Minnesota Medical Foundation

2010: Junior Faculty Award, American Diabetes Association

2015: Faculty Fellow Award, Texas A&M AgriLife Research

2017: Innovative Basic Science Award, American Diabetes Association

2020: Presidential Impact Fellow, TAMU

B. Other honors

Member of special editorial board

Chinese Journal of Gastroenterology and Hepatology, 2005 - 2008

ASN/IFT Grant Writing Workshop

A grant writing workshop for American Society of Nutrition/Institute of Food Technologists (ASN/IFT) member teams for research at the nutrition-food science interface, 04/14/2008 – 04/15/2008.

Ten proposals were selected based on likelihood for success for federal funding based on the biosketches of the investigators and the proposed research aims. Selection was made nationwide.

Member of peer-review committee

American Heart Association, Study Section of Vascular Wall Biology and Atherosclerosis. 2010-2015, 2016-present

Editorial board

Journal of Nutrition and Food Science, 2010 – present

American Journal of Digestive Disease, 2014 – 2018

Journal of Nutritional Biochemistry, 2016 – present

Editor, Special Issue

Journal of Nutritional Biochemistry, 2021 – 2022

Member of peer-review committee

2011-present

Life Science and Medical Science Sections, Chinese National Science Foundation

Early Career Reviewer

2012 Feb

Cellular Aspects of Diabetes and Obesity Study Section – CADO, National Institutes of Health (NIH/NIDDK)

Ad hoc Reviewer

2013 Dec, 2014 Feb, 2015 Oct

Integrative Physiology of Obesity and Diabetes Study Section – IPOD, NIH/NIDDK

2014 Feb

Heart, Lung, and Blood Program Project Review Committee – HLBPP/NIH

2015 June & 2016 June

Cellular Aspects of Diabetes and Obesity Study Section – CADO, NIH/NIDDK

2016 June

Integrative Nutrition and Metabolic Processes Study Section – INMP/NIH

2016 November

ZRG1 DKUS P-54 Special Emphasis Panel, NIH

2017 June

Support of Competitive Research (SCORE) program, NIH

2017 June

Diabetes Complications Consortium (DiaComp), NIH

2017 Oct

ZRG1 EMNR-W (02), NIH

2017 June, 2018 June

NIDDK DDK-B, NIH/NIDDK

2018 May

NNF, NIFA/USDA

2018 July

ACE, NIH

2018 Oct

HCCS, NIH

2020

DBT/Wellcome Trust India Alliance (India Alliance)

2021

Curriculum Vitae: Chaodong Wu, MD, PhD

External reviewer for University of Oklahoma Health Science Center (OUHSC) & Presbyterian Health Foundation (PHF), PHF Seed Grant Program

2021, 2022

External reviewer for Research Grant of Medical Research Council, United Kingdom

2022

The French National Research Agency (ANR)

2023 July

ZDK1 GRB-C (O2), NIH

2023 Dec

ZRG1 KUDS Y-(03), SEP Panel, NIH (invited, but not be able to attend to conflict in schedule)

2024 Jan

Swiss National Science Foundation (SNSF)

2024 Mar through Oct

NMHD/NIH; ZRG1 IIDB-X/NIH; ZDK1 GRB-C/NIH

Standing Member

2019, July - 2023 March

HCCS, NIH

Vice Chair

2021, March

Chair

2021, July - 2023 March

HCCS, NIH

2024, Sept

RC2 ZDK1 GRB T/NIH

2014 NIDDK New PI Workshop, December 2-3, 2014

Only PIs with NIH/NIDDK-funded R01 grants were invited to participate in the workshop for them to prepare R01 renewal.

2019 NIAAA-NIDDK Research Workshop, Sept 16-17, 2019

Invited to participate in research workshop: Alcoholic and Nonalcoholic Steatohepatitis: Pathogenesis and Mechanisms of Liver Injury.

C. Other Relevant Accomplishments Summary (Since appointment at TAMU)

Year	Type of Accomplishments
------	-------------------------

Curriculum Vitae: Chaodong Wu, MD, PhD

2010	Press release: Gene action may lead to diabetes prevention, cure
2012	Press release: Is there a 'healthy' obesity gene?
2012	Recognition by TAMU President (President's newsletter)
2014	Press release: It's all in the timing
2018	Press release: Texas A&M Today: Texas A&M-led Collaborative Study Takes Aim At Non-Alcoholic Fatty Liver Disease
2018	Press release: Texas A&M Today: Study shows 'precision nutrition' may help prevent non-alcoholic fatty liver disease
2020	Press release: Texas A&M Today: Natural Compound In Vegetables Helps Fight Fatty Liver Disease
2022	Press release: Texas A&M Today: AgriLife Research-led study examines nonalcoholic fatty liver disease